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Osteoarthritis of the knee is a chronic disease leading to considerable burden on 
health. Pain, while not always present is the most prominent clinical feature and the 
cause of significant disability. There are a wide variety of treatment options available 
to patients, many with substantial side effects or contraindications for use. However, 
these options have modest effects at best and target symptoms rather than the 
disease. 
Pulsed electrical stimulation (PES) is an electrotherapy treatment modality using 
capacitively coupled, pulsed, monophasic current with a frequency of 100Hz, 
delivered at sub-sensory intensity. It has been reported to produce positive outcomes 
for pain, function and physician global assessment in short-term randomised 
controlled trials (four and 12 weeks) and longer term longitudinal studies. It is 
relatively inexpensive, non-pharmaceutical, non-invasive and has few side effects. 
Despite all this its use is not widespread. In addition, PES has a putative disease-
modifying action through its ability to stimulate chondrocyte activity and type II 
collagen formation. 
The aim of this doctoral research was to investigate the effectiveness of PES in 
treating osteoarthritis of the knee by measuring pain, function, patient global 
assessment, quality of life and physical activity over a period of 26 weeks.  
In order to do this, an initial pilot study using commercially available PES equipment 
was conducted. The aims of this small study following three participants over 16 
weeks were to investigate whether reported improvement was maintained over the 
longer period of time and to pilot test the materials, process and equipment being 
considered for a subsequent randomised controlled trial. This study provided 
evidence to suggest that the longer term randomised controlled trial was warranted. 
The next phase of this doctoral research centred around the development of the PES 
and placebo-PES equipment. Initial testing of the equipment that was made to 
replicate the parameters reported in the literature produced unacceptable adverse skin 
reactions. As a consequence, further consideration was given to electrical treatment 
parameters and a second prototype containing pulsed, asymmetrically biphasic 
current with a frequency of 100Hz was developed and tested.  
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A cross-sectional study of 25 healthy adults with no contraindications to 
electrotherapy was undertaken to compare the rate of adverse skin reactions after 
using the replicated monophasic device with that after using the asymmetrically 
biphasic device. These rates were also compared with the rates of adverse skin 
reactions cited in the PES literature. Thirteen (52%) participants experienced an 
adverse skin reaction after using the monophasic prototype device, while one (4%) 
participant demonstrated an adverse skin reaction after using the biphasic prototype 
device. Additionally, the rate for the monophasic prototype differed significantly 
from the reported rates in three of the four published studies (p<0.04). These results 
gave strong support for the use of the biphasic current in the proposed randomised 
controlled trial. 
In order to investigate the effectiveness of PES in treating people with osteoarthritis 
of the knee, a double-blind, randomised, placebo-controlled, repeated measures trial 
was undertaken over 26 weeks. Seventy people were randomised to either the PES or 
placebo group. Outcome measures included pain, function, patient global assessment, 
quality of life, physical activity and global perceived effect. At the end of the study at 
26 weeks, there was a statistically significant improvement in pain visual analogue 
scale (p≤0.001) in both groups. However, there was no difference between the 
groups (mean change difference 0.9mm; 95% confidence interval -11.7mm to 
12.5mm). Similarly no differences were found between the groups in any of the other 
outcome variables. These results conclude that in this particular sample of people 
with mild to moderate symptoms and impairment, and moderate to severe 
radiographic osteoarthritis of the knee, PES used over 26 weeks was no better than 
placebo. 
Osteoarthritis of the knee is a chronic condition. People suffering pain and disability 
from the disease need to be able to make informed choices about best available 
treatment options. This doctoral research provides independent evidence of the 
effectiveness of PES. In doing so it adds to the body of evidence available to assist 
those with osteoarthritis and their health care providers in making treatment choices. 





The road towards PhD completion cannot successfully be travelled alone. I would 
like to thank the following people and organisations for their generous assistance, 
contribution and support throughout my journey. 
Associate Professor Kathy Briffa, my chief supervisor and mentor extraordinaire. 
Thank you for taking me on as your student, for your unfailing support and 
encouragement, for allowing me the freedom to develop at my own pace, for 
respecting my previous professional experience while understanding my limitations 
and inexperience as a novice researcher, and for teaching me so very, very much. My 
PhD experience would have been much the poorer without you guiding my way. 
Associate Professor Tom Briffa, associate supervisor. Thank you for your incredible 
diligence and support throughout my entire PhD journey from the pilot study when 
teaching me about accelerometer data through to the final results of our RCT. 
Associate Professor Graeme Carroll, associate supervisor. Thank you for your 
consistent and quiet support, always there when needed to provide clinical expertise 
and advice through many draft reports. 
Chris Tingley, Senior Biomedical Engineer at Sir Charles Gairdner Hospital. 
Without your expertise, there would have been no E-PES PhD. Your patience as we 
developed and tested the various electrical devices was phenomenal. No hurdle or 
obstacle during the development phase was too difficult to overcome. Thank you for 
being so generous with your time and knowledge. 
Mandy Monks, your cheerful assistance, incredible willingness to help and amazing 
attention to detail during the first half of the randomisation process was greatly 
appreciated. Many thanks also for your formatting advice and assistance in the latter 
stages of thesis preparation. 
Suzanne James. Thank you for so ably taking over from Mandy with randomisation 
at the halfway mark. Your very willing and accommodating assistance in this regard 
was also greatly appreciated. 
Thank you to Dr Ritu Gupta, statistician, for early input when planning the RCT and 
for creating the computer-generated randomisation system used. 
viii 
 
Thanks also to Dr Richard Parsons, statistician, for assisting with final data analysis 
of the RCT. Your complex deliberations were most appreciated. 
Paul Davey. Thank you for writing the program that enabled speedy collation of 
accelerometer data into spreadsheets.  
Arthritis Australia State and Territory Research Grant in Aid, Physiotherapy 
Research Foundation Seeding Grant, and the School of Physiotherapy at Curtin 
University Early Career Researcher Research Grant for funding without which the 
research could not have been undertaken. 
The Australian Postgraduate Award PhD Scholarship and the School of 
Physiotherapy Health Through Movement Scholarship for providing financial 
support throughout this academic endeavour. 
Penny Roe and Joan de Castro, very special friends who, perhaps against their better 
judgement asked how my research was going on a regular basis. Thank you for your 
interest, for listening and for helping out in ways too numerous to mention. 
To all the people who volunteered to participate in the three studies a huge thank 
you. 
To my faithful, four-legged, canine companion Kalimba who provided calm and 
steadfast company throughout the many hours that I spent seated at the computer. 
What wonderful support you gave me. 
To my parents Kevin and Marion Fary, for supporting me during my early years of 
education and setting me on the pathway of life-long learning, a big thank you. 
Finally to my most important support network, my husband Jim Flynn and son 
Brendan. Your unswerving support, love and encouragement made this thesis 
possible. Having you both firmly by my side throughout this personal learning 
journey of mine has meant the world to me. 
 




List of publications 
Fary RE, Carroll GJ, Briffa TG, Gupta R, Briffa NK (2008) The effectiveness of 
pulsed electrical stimulation (E-PES) in the management of osteoarthritis of the knee: 
a protocol for a randomised controlled trial. BMC Musculoskelet Disord 9:18 
doi:10.1186/1471-2474-9-18. 
 
Fary RE, Briffa NK, Briffa TG (2009) Effectiveness of pulsed electrical stimulation 
in the management of osteoarthritis of the knee: three case reports. Physiother 
Theory and Pract 25(1):21-29. 
 
Fary RE, Briffa NK (2010) Monophasic electrical stimulation produces high rates of 
adverse skin reactions in healthy subjects. Physiother Theory and Pract Aug 8 [Epub 
ahead of print]. 
 
Fary RE, Carroll GJ, Briffa TG, Briffa NK. The effectiveness of pulsed electrical 
stimulation (E-PES) in the management of osteoarthritis of the knee: results of a 





Fary RE, Briffa NK, Carroll GJ, Briffa TG, Gupta R (2007) Effectiveness of pulsed 
electrical stimulation (E-PES) in the management of osteoarthritis of the knee: a 
randomised controlled trial protocol. Australian Rheumatology Society (Western 
Australian Branch) Scientific Meeting, Perth, September. 
 
Fary RE, Carroll GJ, Briffa TG, Briffa NK (2010) Pulsed electrical stimulation is no 
better than placebo in the treatment of osteoarthritis of the knee: a randomised 
controlled trial. Annual European Congress of Rheumatology EULAR 2010, Rome, 






Fary RE, Carroll GJ, Briffa TG, Briffa NK (2009) Effectiveness of pulsed electrical 
stimulation in the treatment of osteoarthritis of the knee: a randomized controlled 
trial. American College of Rheumatology Annual Scientific Meeting, Philadelphia, 
USA, October. Arthritis and Rheumatism 60 (Abstract Supplement). 
 




List of abbreviations 
AC Alternating current 
AAS Adjusted activity score 
ACR American College of Rheumatology 
ATP Adenosine triphosphate 
BMI Body mass index 
BPES Biphasic pulsed electrical stimulation 
CONSORT Consolidated Standards of Reporting Trials 
DC Direct current 
E-PES Effectiveness of pulsed electrical stimulation 
GPES Global perceived effect scale 
HAP Human Activity Profile survey 
IFT Interferential therapy 
LCD Liquid crystal display 
MAS Maximal activity score 
MCII Minimal clinically important improvement 
MCS Mental component summary  
MPES Monophasic pulsed electrical stimulation 
MRI Magnetic Resonance Imaging 




OAK Osteoarthritis of the knee 
OARSI Osteoarthritis Research Society International 
OMERACT Outcome Measures in Rheumatology Clinical Trials 
PCS Physical component summary 
PEMF Pulsed electromagnetic field 
PES   Pulsed electrical stimulation 
PGA Patient global assessment 
QoL Quality of life 
RCT Randomised controlled trial 
SF-36 Medical Outcomes Study Short-Form 36 Survey 
TENS Transcutaneous electrical nerve stimulation 
TKR Total knee replacement 
VAS Visual analogue scale 
WOMAC Western Ontario and McMaster Universities Osteoarthritis Index 
 




Table of Contents 
Abstract  v 
Acknowledgements vii 
List of publications ix 
List of abbreviations xi 
Table of Contents xiii 
Chapter 1: Review of the literature, rationale for thesis and study design 1 
1.1 Introduction and overview of osteoarthritis of the knee 1 
1.2 Pulsed electrical stimulation 3 
1.2.1 Defining the pulsed electrical stimulation modality 3 
1.2.2 Pulsed electrical stimulation clinical trials 4 
1.2.3 Pulsed electrical stimulation and articular cartilage 9 
1.2.4 Summary 11 
1.3 Pain 11 
1.3.1 Pain mechanisms in osteoarthritis 11 
1.3.2 Pain mechanisms and electrical stimulation 16 
1.3.3 Summary 17 
1.4 Functional ability and quality of life 18 
1.4.1 Functional ability and quality of life in the osteoarthritis population 18 
1.4.2 Relationship between pain and disability in osteoarthritis 20 
1.4.3 Summary 21 
1.5 Physical activity 21 
1.5.1 Defining physical activity 22 
1.5.2 Physical activity in the osteoarthritis population 22 
1.5.3 Joint pain, function and physical activity 23 
1.5.4 Summary 24 
1.6 Rationale for thesis 24 
1.6.1 Study design 25 
1.6.2 Measurement of pain 27 
xiv 
 
1.6.3 Measurement of patient global assessment 27 
1.6.4 Measurement of health status - function and quality of life 27 
1.6.5 Measurement of joint stiffness 29 
1.6.6 Measurement of physical activity 29 
1.6.7 Measurement of overall perceived improvement 30 
1.6.8 Thesis plan 31 
1.7 Summary and significance 32 
Chapter 2: Pilot study of pulsed electrical stimulation 33 
Chapter 3: Development of pulsed electrical stimulation equipment 45 
3.1 Introduction 45 
3.2 Choice of equipment 46 
3.3 Electrical stimulation waveforms 47 
3.4 Placebo device 47 
3.5 Electrodes and mechanism for capacitive coupling 49 
3.6 Coupling gel 51 
3.7 Batteries 51 
3.8 Instruction manual 52 
3.9 Summary 53 
Chapter 4: Prototype equipment testing study 55 
Chapter 5: The effectiveness of pulsed electrical stimulation (E-PES) trial 
research protocol 63 
Chapter 6: The effectiveness of pulsed electrical stimulation (E-PES) in the 
management of osteoarthritis of the knee: results of a randomised 
controlled trial 75 
Chapter 7: Summary and main findings 103 
7.1 Introduction 103 
7.2 Pilot study of pulsed electrical stimulation 104 
7.3 Development of pulsed electrical stimulation equipment 105 




7.4 Prototype equipment testing study 106 
7.5 Effectiveness of pulsed electrical stimulation trial research protocol 108 
7.6 Results of the E-PES trial 110 
7.6.1 Comparison with other trials 110 
7.6.2 Placebo 113 
7.6.3 Sample characteristics 113 
7.6.4 Physical activity 114 
7.6.5 Strengths of the E-PES trial 115 
7.6.6 Limitations of the E-PES trial 116 








Chapter 1: Review of the literature, rationale for thesis and 
study design 
1.1  Introduction and overview of osteoarthritis of the knee 
Osteoarthritis (OA) is a major cause of pain and disability in the community and OA 
of the knee (OAK) is one of the most common causes of musculoskeletal disability 
in the Western world (Walker-Bone et al. 2000). It contributes significantly to the 
worldwide burden of health (Felson et al. 2000; Walker-Bone et al. 2000; Symmons 
et al. 2003; Woolf and Pfleger 2003; Buckwalter et al. 2004; Buckwalter and Martin 
2006; Sharma et al. 2006) and imposes a substantial financial cost on the Australian 
community (Segal et al. 2006; Access Economics 2007). The progressive and 
chronic nature of the disease exacerbates the forecasted health burden (Holt et al. 
2010) so efforts to improve the long term management of the disease are therefore 
essential. 
While pain is not always present with diagnosed OAK it is, when present, considered 
the most prominent clinical feature (Altman and Dean 1989; Woolf and Akesson 
2001; Fernihough et al. 2004; Gwilym et al. 2008) and the most important 
determinant of disability (McAlindon et al. 1993; van Baar et al. 1998; Sharma et al. 
2003; Torres et al. 2006; Somers et al. 2009). Pain is usually activity related, but may 
be present at rest in some patients, especially in more advanced disease (Sale et al. 
2008). 
Other clinical features include: bone and joint tenderness; crepitus; decreased range 
of joint motion; variable degrees of local inflammation with heat and swelling, which 
may be due in part to joint effusions; and loss of function (Altman et al. 1986; 
Symmons et al. 2003). People with OAK are also likely to demonstrate lower activity 
levels than those without OAK (Bennell et al. 2004; Farr et al. 2008). 
The disease process itself is a complex one characterized by articular cartilage 
degeneration, but essentially affecting all joint structures. Common features include 
hypertrophy of bone (osteophytes and subchondral bone sclerosis), bone oedema, 
subchondral cysts, thickening of synovium and joint capsule, ligamentous laxity and 




periarticular muscle weakness (Felson et al. 2000; Iannone and Lapadula 2003; 
Sarzi-Puttini et al. 2005; Brandt et al. 2006; Goldring and Goldring 2007).  
The diagnosis of OAK may be based on clinical findings, for example, the combined 
presence of pain, crepitus on movement, bony tenderness and enlargement; on 
radiographic evidence, for example, decreased joint space width, presence of 
osteophytes, presence of subchondral bone sclerosis and cysts; or a combination of 
both clinical and radiographic findings (Altman et al. 1986). 
A wide variety of effective treatment options that target symptoms and function are 
currently available. These include, but are not limited to: medication (predominantly 
non-steroidal anti-inflammatory agents and analgesics); nutritional supplements 
(glucosamine, chondroitin sulphate, fish oil), exercise and self-management 
programs, and surgery. Some physiotherapists also use various electrotherapy 
modalities such as ultrasound, transcutaneous electrical nerve stimulation (TENS) 
and interferential therapy to address pain, inflammation and swelling.  
The variety of available treatment options reflects the diversity of clinical 
presentations and the heterogeneity of the disease. It also may reflect the modest 
effect sizes achieved with many of these options (Zhang et al. 2010) and that adverse 
effects and complications in the presence of co-morbidities commonly restrict use of 
pharmacological (Gislason et al. 2006; Solomon et al. 2006) and surgical treatments. 
Pulsed electrical stimulation (PES) is a treatment modality that is reported to have 
significant effects in terms of pain management and improvement in function in the 
short term (Zizic et al. 1995; Garland et al. 2007). It is commonly grouped with 
TENS as evidenced in the Cochrane review on TENS use in OAK (Rutjes et al. 
2009) because of its mode of delivery. The clinical guidelines developed by the 
Philadelphia Panel (Harris and Susman 2002), Osteoarthritis Research Society 
International (OARSI) (Zhang et al. 2010) and Royal Australian College of General 
Practitioner Osteoarthritis Working Group (March et al. 2010) all recommend TENS 
for treating OAK. 
This modality is of particular interest as in vitro and animal studies suggest it also 
has disease-modifying potential (Lippiello et al. 1990; Wang et al. 2004; Brighton et 
al. 2006; Brighton et al. 2008). To date, only relatively short-term randomised 
  Review of literature, rational for thesis and study design 




controlled trials (RCT) have been conducted to investigate its effectiveness. 
Therefore, whether symptomatic and functional benefits are maintained or whether 
they increase with ongoing use is unknown. Additionally, there are no data to address 
whether the putative disease-modifying effects occur in vivo in humans.   
Given the encouraging published reports, apparent ease of use and the potential for 
OA disease modification, it is surprising that the use of PES is not more widespread.  
Limitations in the study designs and reporting of previous PES research may have 
contributed to this situation. Nevertheless it remains a modality of interest and 
worthy of further investigation. The aim of this thesis was therefore to investigate the 
capacity of PES to produce sustained improvement in symptoms and function in 
people with OAK over 26 weeks.  
1.2  Pulsed electrical stimulation  
1.2.1   Defining the pulsed electrical stimulation modality 
Pulsed electrical stimulation treatment is the application of any electrical waveform 
that has an interrupted flow of current (Walsh 2008). That is, it may be an alternating 
(AC) or direct (DC) current with any wave shape but it must periodically cease flow 
and, in so doing, create pulses of current stimulation (Walsh 2008).  Whilst this 
seems simple enough, the diversity of current sources and the variety of methods of 
application leads to terminology that can vary in ways that does not always seem 
logical. 
In this thesis, the term PES will specifically refer to electrical stimulation delivered 
using capacitive coupling, meaning that the patient forms a part of the electrical 
circuit. This is in contrast to inductive coupling where the patient is not part of the 
circuit. Pulsed electromagnetic field (PEMF) treatment is one such modality. It is 
delivered using inductive coupling and has been extensively studied (Sharrard 1990; 
Trock et al. 1993; Trock et al. 1994; Thawer 1999; Pipitone and Scott 2001; van 
Nguyen and Marks 2002; Thamsborg et al. 2005). Two systematic literature reviews 
combine these two different interventions, PES and PEMF, citing the pulsed nature 
of the treatment (McCarthy et al. 2006) and the ultimate creation of an electrical field 
in the tissue (Hulme et al. 2002) as justification for the combined review. While there 
is merit in both these assumptions they ignore the fact that a pulsed TENS 




application also fits these criteria yet TENS is excluded from these reviews. 
Additionally both reviews ignore the possibility that actual current flow through the 
tissue and the tissue being part of the circuit may both be important determinants of 
effectiveness. 
Differentiating PES as a distinct treatment modality from other forms of capacitively 
coupled electrotherapy treatments commonly used in clinical practice, such as TENS 
and interferential, also raises questions. While there are specific electrical features 
that characterize each of these modalities (Johnson 2008; Palmer and Martin 2008), 
the major distinction between electrotherapy treatments like TENS and interferential 
on the one hand, and what is traditionally labelled PES in the literature on the other is 
that PES is delivered to patients at a sub-sensory intensity. That is, patients using 
PES should feel no electrical stimulation for the duration of treatment. This is in 
direct contrast to other capacitively coupled electrotherapy modalities where 
sensation of the electrical stimulation and hence stimulation of sensory nerves is an 
objective of the treatment (Roche and Wright 1990; Grimmer 1992; Osiri et al. 2000; 
Johnson 2001; Adedoyin et al. 2002; Cheing et al. 2003; Chesterton et al. 2003; 
Sluka and Walsh 2003; Law and Cheing 2004). 
Another more recent systematic review of TENS use in OAK included PES papers 
(Rutjes et al. 2009). This lends weight to the proposition that capacitively coupled 
electrotherapy modalities share similar characteristics. The review by Rutjes et al. 
(2009) proved to be inconclusive citing small studies of questionable quality as the 
reason for such an outcome. 
Adding further to confusion regarding nomenclature, the US federal agency Centers 
for Medicare and Medicaid Services, refers to the PES device reported in the 
literature as a transcutaneous electrical joint stimulation device system (Farr et al. 
2006).  
1.2.2   Pulsed electrical stimulation clinical trials 
The first reported clinical trial using PES was a multi-centre, double blind, 
randomised, placebo-controlled study using PES over a four week period (Zizic et al. 
1995). This was the only trial publication available at the time of developing this 
thesis. The PES equipment used for this early study was the commercially available 
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Bionicare® BIO-1000™ device (BioniCare Medical Technologies Inc., Sparks, MD, 
USA). The manufacturer’s technical specifications state that this device delivers a 
monophasic, exponentially decreasing, pulsed waveform with a frequency of 100Hz.  
The Zizic et al. (1995) study enrolled 78 participants with OAK and reported positive 
outcomes for the variables pain, function, physician global evaluation (all 10cm 
visual analogue scales (VAS)) and duration of joint stiffness in the morning 
(minutes). Participants were asked to use PES for six to 10 hours per day for the 
duration of the study. Six participants withdrew (four from the placebo and two from 
the active group) and one participant was excluded from analysis because the treating 
physician did not have any other patients in the trial to act as a matched control. 
Reasons for withdrawing included the development of a rash (one placebo and one 
active), one moving away (placebo), one unwell with asthma (active) and two not 
wanting to continue (placebo). Of those who remained, good compliance was 
achieved with 78% active and 67% placebo achieving the target dose. The only 
adverse effects noted were skin rashes under the electrodes that occurred equally 
amongst those using the active device and those using the placebo (24% and 21% 
respectively). This led the authors to contend that the skin reaction was due to the gel 
used rather than the electrical current administered.  
No mean data were published and outcomes were described as percentage 
improvements. These percentage improvements were statistically significant for the 
variables previously mentioned, but in the absence of the mean data, it was difficult 
to determine whether the improvements were of clinical significance.  
Strengths of this study were the use of a credible placebo device and specification of 
primary outcome variables. However, while the study was reported to be a 
randomised trial, details of sequence generation and concealment were not provided. 
Moreover, it is not explicitly stated whether outcome assessors were blind to 
allocation and intention to treat analysis was not applied. Selective reporting of 
results was also evident with outcomes for walking time, tenderness and swelling as 
mentioned in the methods not included in results. 
The discussion by Zizic et al. (1995) related the potential benefits of PES on articular 
cartilage to the study’s outcomes. However, symptomatic improvement after four 




weeks cannot reasonably be attributed to changes in the articular cartilage nor was 
this potential variable measured.  
A second multi-centre, double blind, randomised, placebo-controlled trial of PES 
was reported by Garland et al. (2007). This study was published after research 
funding had been established and thesis development was well underway. 
Participants had moderate to severe OAK characterised by unequivocal radiological 
changes (Kellgren-Lawrence score of 3 or 4) and persistent pain despite non-
steroidal anti-inflammatory drug (NSAID) and/or analgesic treatment. 
The trial asked participants to use the same PES device as Zizic et al. (1995) for a 12 
week period (six to 14 hours per day). It measured pain and other symptoms (0-100 
VAS), pain (Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC)), stiffness (WOMAC), function (WOMAC) and patient global 
assessment (PGA) (0-100 VAS). The randomisation to devices procedure was 
conducted, by an observer independent of the study, at a ratio of 2:1 (active:placebo) 
for the 58 participants. This meant that results were reported for 39 participants using 
the active device and 19 using the placebo. A further 42 participants, all from one 
clinic, who had been enrolled and randomised were excluded from analysis after it 
was reported that a number of those had been given other treatments in addition to 
the study treatment. Of the 58 whose results were analysed, 63.1% using the active 
device and 65.8% using the placebo achieved the minimum target dose of six hours 
per day. Adverse skin reactions occurred in 17.9% of those with the active device 
and 21.1% of those with the placebo. 
As in Zizic et al. (1995) percentage changes from baseline were measured. 
Statistically significant differences were reported for all variables apart from pain 
measured by WOMAC. It is assumed that the stated clinically important 
improvements occurring in four of the five variables refers to the 20% improvement 
generally agreed by expert opinion as clinically meaningful (Bellamy et al. 2005; 
Clegg et al. 2006), though this is not explicitly stated. Mean data tables demonstrated 
substantial real differences between the two groups. However, only WOMAC 
function achieved the minimal clinically important improvement described by 
Tubach et al. (2005) and neither of the two key variables of pain or function achieved 
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the absolute mean change of 20 that is required to meet the primary OARSI 
responder criteria (Pham et al. 2004).  
In addition to changes from baseline, the percentage of participants experiencing a 
50% improvement in outcomes was compared between the groups. Significant 
differences were noted in three of the five variables – PGA, pain and other symptoms 
VAS and WOMAC pain – between the groups. 
Once again, the use of a credible placebo device was a strength of this study. 
Adequate sequence generation and adequate concealment of allocation were 
reported. However, there were no explicitly specified primary outcomes and 
intention to treat analysis was not applied. Additionally, while ongoing analgesic use 
was allowed for all participants it is not reported whether use was similar between 
the two groups. No power calculations were presented and due to the small number 
of participants in the placebo group, it is difficult to determine the true meaning of 
the results. The exclusion of all 42 randomised participants from one clinic raises the 
risk of bias in the study. The WOMAC VAS function subscale has a score range 
from zero to 1700. However, Garland et al. (2007) cite this range as from zero to 
850. This suggests that around half of the WOMAC function subscale questions were 
either excluded or not reported, or that a different scoring regime to that 
recommended was implemented. As a result, further risk of bias from selective 
reporting cannot be excluded. Finally, unsubstantiated claims were made about how 
long the effects tended to last after cessation of PES. No studies to support this claim 
have been found and none are cited in this paper.  
Of particular note, the placebo changes in both studies (Zizic et al. 1995; Garland et 
al. 2007) were minimal. This is at odds with general reports in the OA literature 
where the placebo effect is usually observed to be considerable (Zhang et al. 2008) 
and consistently present across a range of modalities from neutraceuticals to 
arthroscopy (Moseley et al. 2002; Clegg et al. 2006). Apart from the potential risk of 
bias from excluding 42 participants and selective reporting there is no other 
indication from the published data why these two PES studies should have achieved 
the notable absence of a placebo response. 
Two other clinical trials using the Bionicare® device have also since been reported. 
Mont et al. (2006) conducted a multi-centre, prospective, four year open label, 




longitudinal study, that enrolled 157 participants and used PES for eight plus or 
minus two hours daily for an initial period of one year. After the first year, 
participants could elect to continue to use the device for a further year until the end 
of the study at four years duration. All participants had OAK to the extent that all had 
been given advice that a total knee replacement (TKR) was warranted. The primary 
aim of the study was to determine whether use of PES could defer the decision to 
have replacement surgery. Secondary aims were to determine changes in the 
outcomes of physician’s global assessment, patient’s pain and symptoms, and 
function (all using a 10cm VAS). A comparison group of patients treated with TKR 
some 10 years prior were included in the analysis. 
Compared with the group from 10 years prior, there was a statistically significant 
difference in rates of TKR deferral in the group using PES. The difference in deferral 
rates was most significant for those people classified as having severe symptoms at 
baseline. Within the PES group those who chose to have a TKR at some point during 
the four year period experienced significantly less improvement in the three 
secondary outcome measures than those who deferred the surgery. Adverse skin 
reactions occurred in 45% of participants. This is a higher number than that reported 
in the two RCTs and may reflect the greater length of time of usage. It also may be 
due to the type of gel used but this was not reported. 
While this study reported positive results with the use of PES, there are a number of 
issues that arise from using a comparison group from some 10 years prior. No data 
comparing medication between the two groups are cited. Data collected during usual 
medical care in the 10 year prior group may be affected by unknown confounding 
factors, for example different health professionals collecting the data. It may be that 
increasing health care costs influenced the PES participants’ decisions to delay 
undergoing an expensive procedure rather than their responses to PES treatment 
alone. Finally, advancement in pain management strategies during the 10 year period 
cited (1983-1993) could well have led to improved medical and self-management 
control of the symptoms in the experimental group which in turn may have 
contributed to the decision to defer surgery.  
Farr et al. (2006) investigated the use of PES in 288 people who had failed non-
operative treatment for OAK symptoms. In a prospective, longitudinal study 
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conducted over a two year period, the relationship between hours of use and effect 
size was studied. A dose-response relationship was reported to exist. Those who used 
the device for more than 750 hours over the study period were found to demonstrate 
significantly better responses in the outcome measures of patient assessment of 
disease activity in the joint, patient assessment of pain and investigator assessment of 
disease activity, all measured on a five point Likert scale. Additionally, improvement 
in all these variables measured from baseline to end of the study was found to be 
statistically significant. Being a study where all participants knew they were 
receiving treatment there is a risk of expectation bias towards a positive outcome. 
This type of study is also open to selection bias. That is, those participants who are 
gaining improvement are more likely to continue to use the treatment and therefore 
artificially inflate the does-response relationship. 
1.2.3   Pulsed electrical stimulation and articular cartilage 
While clinical trials to date have focused on symptomatic effectiveness of PES, 
animal and laboratory studies have focused on its capacity to positively affect 
articular cartilage. In many ways it is this potential to modify the cartilage pathology 
in OA that has sparked much of the interest in the modality, and which has generated 
impetus to determine its symptomatic effectiveness. For articular cartilage changes to 
be confidently measured radiologically, a period of at least 12 months and preferably 
two years between measurements is warranted (Cicuttini et al. 2004). Consequently, 
compliance over such a period of time would likely be enhanced considerably if PES 
provided some symptomatic benefit to patients as well. 
Hyaline articular cartilage absorbs load forces and facilitates smooth movement in 
joints. It is a metabolically active tissue that relies on external influences for nutrition 
in the absence of nerve and blood supply. Chondrocytes are sparsely scattered and 
embedded within an extracellular matrix. The matrix is made up of collagen fibres 
enmeshed with aggrecan (proteoglycan) aggregates. Negatively charged sulphate and 
carboxyl groups along the glycosaminoglycan chains of aggrecan molecules in the 
matrix provide the cartilage tissue with an endogenous electrical potential while 
dissolved electrolytes in solution in the matrix neutralise the sulphate charges (Mow 
et al. 1999) . 




External forces, such as weight-bearing affect the flow of fluid through the matrix. 
This in turn breaks off the neutralising ions from the glycosaminoglycan chains and 
creates a streaming potential within the cartilage (Schmidt-Rohlfing et al. 2002) . It is 
thought that this electrical action stimulates chondrocyte activity and molecular 
activity (Kim et al. 1995). Brighton et al. (2006) postulate that there is a disruption to 
this normal flow in diseased cartilage with consequent interruption to the normal 
metabolic state of the cartilage. 
The capacity of externally applied electric and electromagnetic fields to positively 
affect osteoblast and chondrocyte proliferation and extracellular matrix protein 
production in vitro and in animal studies has been well documented (Lippiello et al. 
1990; Thawer 1999; Aaron et al. 2004). At present, the specific mechanisms whereby 
externally applied electric currents stimulate cartilage matrix production and 
chondrocyte activity are not fully understood. However, there is growing support that 
the mechanism through which this occurs relates to the ability of electrical 
stimulation to enhance chondrocyte differentiation and to up-regulate the expression 
of matrix genes and products (Ciombor et al. 2003; Wang et al. 2004; Brighton et al. 
2006; Brighton et al. 2008).  
Brighton et al. (2006; 2008) report results obtained after applying capacitively 
coupled electrical stimulation to both bovine articular and human articular cartilage 
explants in vitro. Explants were used as they are thought to more closely mimic the 
in vivo situation where chondrocytes are embedded within their native extracellular 
matrix. This is in contrast to earlier work where the stimulation was applied to foetal 
bovine chondrocytes in mass culture (Wang et al. 2004). In both studies, specific 
capacitively coupled electric fields resulted in significant up-regulation of the 
expression of selected extracellular matrix genes (aggrecan and type II collagen) as 
well as total proteoglycan and collagen production in the experimental specimens 
when compared to the controls. This work provides strong theoretical support for the 
use of electrical stimulation to maintain and repair articular cartilage in the clinical 
setting. 
Interestingly, while specific electrical regimes for enhancing chondrogenesis were 
reported in the different laboratory studies, there was considerable variability among 
them. Lippiello et al. (1990) used direct current with frequency 100Hz while the 
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Brighton and Wang teams (Wang et al. 2004; Brighton et al. 2006; Brighton et al. 
2008) used alternating current with frequency 60kHz. This raises the question as to 
how important is the specificity of current type, frequency and electrical field 
strength in achieving chondrogenetic effects? 
1.2.4   Summary 
Ambiguity in the PES terminology obviously exists, possibly as a result of 
companies trying to differentiate their product from others on the market. Essentially, 
PES, like TENS and interferential, is a transcutaneous electrical stimulation 
modality. While in the future it may be more informative to describe it thus, while 
still specifying its electrical properties and delivery characteristics, the term PES is 
used in this thesis to provide consistency with the current literature regarding sub-
sensory, capacitively coupled stimulation. 
With reference to the clinical trials reviewed here, it is of note that all were 
conducted with support from, and by several employees of, BioniCare Medical 
Technologies Inc. the company that manufactured the PES device tested. This 
introduces potential conflict of interest and bias into all of these studies. The 
rationale for use of PES in all of these studies was its potential for disease-modifying 
actions through its putative effects on articular cartilage, yet in none of these studies 
was assessment of the articular cartilage undertaken nor was there any attempt to 
explain how changes to cartilage could result in the rapid improvement of symptoms. 
Nevertheless, as all studies reported positive symptomatic outcomes there remained a 
strong need for an independent investigation into the effectiveness of this non-
pharmaceutical, non-invasive treatment option.  
The putative disease-modifying potential of PES is supported by sound laboratory 
and animal research but remains untested in vivo in humans. This aspect is not 
addressed in this thesis. 
1.3  Pain  
1.3.1   Pain mechanisms in osteoarthritis 
While pain is one of the most commonly reported symptoms in OA (Altman and 
Dean 1989; Creamer 2000; Fernihough et al. 2004; Gwilym et al. 2008) the exact 
pain mechanisms in OA remain elusive (Felson 2005; Kidd 2006; Gwilym et al. 




2008). The presence of an inflammatory process is a well-documented phenomenon 
and suggests a logical pain production pathway. Likewise there is much in the 
specific pathology of OA that can reasonably cause pain, while development of 
peripheral and central sensitization and the impact of psychosocial factors are also 
likely contributory factors in a disease where chronic pain is a common feature.  
1.3.1.1 Inflammation 
It is widely agreed that the pro-inflammatory mediators present in the osteoarthritic 
joint, which initiate the signalling cascade to sensory nerve endings via ion channels, 
contribute to the production of pain (Bhave and Gereau 2004). The widespread use 
and effectiveness of anti-inflammatory medication in treating pain in OAK supports 
this pain mechanism (Hochberg 2001; Sarzi-Puttini et al. 2005; Alvarez-Soria et al. 
2008).   
Inflammation within the synovium is reported to be an important cause of pain in 
those with OAK (Goldring 2009). Hill et al. (2007) showed an association between a 
change in synovial thickening measured using magnetic resonance imaging (MRI) 
and a change in pain measured on a VAS over periods of 15 and 30 months. 
However, while inflammation of the structures affected in OA is a likely contributor 
to pain production, Brenner et al. (2004) provide contradictory evidence stating that 
pain in OA is not primarily of inflammatory origin. They examined the 
concentrations of a variety of inflammatory markers (prostaglandin E2, thromboxane 
B2, nitric oxide, interleukins -6, -1alpha and -1 beta and tumour necrosis factor 
alpha) and enzymes (COX-2 and inducible nitric oxide synthase) in the synovial 
fluid and synovial membranes of patients with OAK undergoing arthroscopy. The 
authors compared these concentrations with measures of clinical features (pain VAS 
and WOMAC) and radiological disease severity (Kellgren-Lawrence scores). Their 
results showed that the concentration of inflammatory markers and enzymes 
generally reflected those found in synovial fluid and membrane in previous OA 
studies. However, the only significant relationship found was between prostaglandin 
E2 and WOMAC scores once corrected for age and body mass index (BMI). This 
demonstrated that the presence of most inflammatory markers and enzymes were not 
related to the amount of pain, dysfunction and stiffness experienced, nor were they 
related to the radiological severity of the disease. A limitation of this study was the 
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restriction on the size of the synovial membrane collected that may have led to some 
synovial changes being missed.  
Further studies using diagnostic ultrasound to investigate the relationship between 
synovitis, effusion and pain in OA have shown poor correlation (Conaghan et al. 
2005; Keen et al. 2008; Song et al. 2008). These reports further support the 
contention that factors other than inflammation contribute significantly to pain 
production in OA. 
1.3.1.2 Pathological changes 
Because articular cartilage is aneural, its degeneration alone is unlikely to cause pain 
in OA. Other structural changes that may contribute to pain include: periosteal 
stretching associated with osteophytes; decreased cartilage volume; raised 
intraosseous pressure; subchondral bone microfractures; bone marrow oedema; 
ligament damage; capsular tension; and meniscal damage (Altman and Dean 1989). 
However, when comparing radiological findings of these features with reports of 
pain, the link between pathological features and pain remains unclear. 
It is generally agreed there is discordance between the amount of pain reported and 
the radiographic features of the disease (Hedbom and Hauselmann 2002; Dieppe and 
Lohmander 2005; Bedson and Croft 2008).  Davis et al. (1992) reported that up to 
40% of people with severe radiographic change present symptom free.  
Other research, described below, using a greater range of X-ray views describes 
some association between symptoms and radiographic findings. However, 
differences in the findings mean that full understanding of the relationship remains 
elusive.  
Cicuttini et al. (1996) reported that the presence of osteophytes was the best 
radiological predictor of pain and reported a stronger relationship between 
osteophytes reported in skyline views of the knee and pain, than that between 
osteophytes found on antero-posterior and lateral views.  Szebenyi et al. (2006) noted 
that people who had structural changes noted on X-ray in both the patello-femoral 
and tibio-femoral compartments were more likely to report pain than those who only 
had one compartment affected. More specifically, they noted that the greatest 
association existed when there was subchondral sclerosis present in both 




compartments.  These results contrast with those of Duncan et al. (2008) who, while 
acknowledging the importance of the patello-femoral joint, determined that it was the 
radiographic severity of the disease within a compartment rather than the specific 
compartment affected that was most related to symptoms. 
More recently Neogi et al. (2009) reported  a strong relationship between frequency, 
consistency and severity of pain, and Kellgren-Lawrence radiographic grades. Using 
a within-subject study design, Neogi et al. (2009) were able to reduce the 
confounding of pain responses that may occur with external influences such as 
psychosocial and cultural factors. However, the study sample from which the 
consistency and severity data were collected included those with knee pain present 
and who had specific risk factors for OAK. This limits the generalisability of the 
study. That is, while some confounding factors were well controlled through study 
design, other potential confounders, such as, selection by phenotype, may have been 
introduced (Pincus and Block 2009). Nevertheless, the results of this large scale 
study provide robust data for consideration. 
Inconsistencies in the relationship between the presence of OA changes found on 
MRI and clinical symptoms are also reported (Link et al. 2003; Kornaat et al. 2006; 
Phan et al. 2006; Kornaat et al. 2007). Kornaat et al. (2006) noted associations 
between the MRI findings of patella osteophytes and pain and between a large joint 
effusion and both pain and joint stiffness. All other MRI findings, including 
subchondral cysts, bone marrow oedema and meniscal tears, among others, were not 
associated with clinical symptoms in this study. Phan et al. (2006) likewise found 
little relationship between changes in MRI findings (including the rate of cartilage 
loss and evidence of bone marrow oedema and ligamentous and meniscal pathology) 
and changes in WOMAC scores measured three times over a period of 2.4 (+/- 0.4) 
years. 
The reasons for the apparent inconsistency between symptoms and radiologically 
reported changes may be due to the variety of tools used to measure symptoms 
and/or radiological procedures (Bedson and Croft 2008); study design factors such as 
between person confounding (Neogi et al. 2009) and subject selection procedures 
(Dekker et al. 1992); or because the pain producing mechanisms are just not visible 
radiologically (Dekker et al. 1992).  
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1.3.1.3 Mechanical changes 
The structural and physiological changes within the OA joint often lead to 
biomechanical changes including reduced joint range of motion, periarticular muscle 
weakness and varus-valgus joint laxity. 
Miura et al. (2009) found an association between pain and the presence of varus-
valgus laxity but not with quadriceps strength. O’Reilly et al. (1998), van Baar et al. 
(1998) and Amin et al. (2009) on the other hand all found strong associations 
between pain and quadriceps strength. Whether quadriceps weakness is mainly a 
result of pain inhibition (Lewek et al. 2004); secondary to other joint structural 
changes such as ligamentous laxity or malalignment; or a primary risk factor for the 
development of OAK and knee pain (Slemenda et al. 1997) is yet to be fully 
determined.  Maly et al. (2008) found that joint range of motion and BMI were 
related to pain levels but not to peak knee adduction moment, varus-valgus 
alignment, range of adduction-abduction during gait or quadriceps strength. Different 
methods were used to assess the variables in the studies. This undoubtedly 
contributes to seemingly contradictory outcomes. In the meantime, the relationship 
between biomechanical factors and pain production remains a complex one.  
1.3.1.4 Nociception and neural sensitization 
Studies that demonstrate decreased threshold for thermal and mechanical stimuli and 
increased background firing in people with OA suggest that some of the pain 
experienced in OA may be due to abnormal pain sensitivity (Hendiani et al. 2003; 
Bhave and Gereau 2004; Bradley et al. 2004; Dray and Read 2007; Kidd et al. 2007).  
McDougall (2006) went further stating that peripheral sensitization of afferent nerves 
within the joint was the main source of pain in arthritis. Bradley et al. (2004) noted 
that people with OA had abnormal pain sensitivity accompanied by greater 
sensitivity at sites away from the affected joint, while Felson (2005) suggested that 
impairment of noxious inhibition at the spinal cord level may also contribute to the 
pain of arthritis.  
That both peripheral and central neural sensitization can occur in people with OAK 
(Dieppe and Lohmander 2005; Grubb 2009; Schaible 2009) is well documented and 
adds to the diversity of pain presentation in OA. 




1.3.1.5 Psychosocial influences 
Psychosocial factors can significantly influence pain perception in people with 
chronic joint pain (Davis et al. 1992; Creamer and Hochberg 1998; Ferreira and 
Sherman 2007; Gwilym et al. 2008) with anxiety, coping style, fear avoidance and 
possible depression being associated with pain and disability (Dekker et al. 1992; 
Rosemann et al. 2008). Psychological characteristics are associated with pain 
perception independent of radiographic presentation and mechanical factors such as 
muscle weakness (van Baar et al. 1998).  
1.3.2   Pain mechanisms and electrical stimulation 
It is clear that the causes of pain and pain mechanisms in OAK are multi-factorial 
and are modulated by psychosocial influences. This heterogeneity could explain the 
varied responses of different individuals to different interventions. Of particular 
interest to this study are those pain pathways that may be influenced by externally 
applied electrical stimulation.  
1.3.2.1 Ion channels and receptor responses 
There are many pain mediating receptors in the periphery that may theoretically be 
affected by an externally applied electrical input by virtue of their endogenous 
electrical potential and the role of polarization in receptor function and nociceptor 
stimulation (Wood 2006).  
Ion channels that allow the passage of ion flow in and out of cells are regulated by 
changes in membrane potential (Schafers and Sorkin 2008) and inflammatory 
cytokines, commonly found in OA, modify ion channel function. In doing so, the 
cytokines contribute to changes in pain response and neuronal excitability. Seegers, 
et al. (2001) hypothesize that the cellular membrane proteins involved in signal-
transduction may be affected by an applied electrical stimulation.  Thus ion channel 
regulation is one possible mechanism whereby externally applied electrical 
stimulation could modify symptoms in OA. 
Seegers et al. (2002) also demonstrated the capacity of monophasic, pulsed electrical 
stimulation to alter adenosine triphosphate (ATP) levels in vitro and in vivo, and 
postulated that altering ATP levels may affect pain sensation through P2-purinergic 
receptors. Their results however, demonstrated completely different ATP production 
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responses in vitro, where it increased, compared with in vivo, where it decreased. 
Hamilton and McMahon (2000) describe how ATP accentuates pain responses. If 
ATP is decreased in vivo as reported by Seegers et al. (2002) it provides an 
additional theory as to how electrical stimulation may act to relieve pain. 
More specifically, voltage-gated ion channels located in primary afferent neurons 
determine the timing and extent of action potential firing by allowing the passage of 
charged ions in and out of cells in response to cellular membrane potential (Schulz et 
al. 2008).  The initiation of increased sensory nerve signalling by inflammatory 
mediators enhances increased background firing and other features of peripheral 
sensitization (Bhave and Gereau 2004). The processes involved in gate activation 
and voltage sensing in these ion channels is complex (Tombola et al. 2006) but 
again, it is feasible that externally applied electrical stimulation may in some way 
influence their responses and subsequently a patient’s pain perception. 
Moderation of ion channel function and receptor activity is clearly an area where 
changes in electrical potential, secondary to externally applied electrical stimulation, 
may affect pain responses.  
1.3.2.2 Inflammatory mediators 
Grubb (2009) states that inflammatory mediators associated with joint damage 
sensitize afferent neurons by binding to receptors at the nerve endings. Two 
laboratory studies, investigating the effect of externally applied electrical stimulation 
on bovine articular cartilage explants and human articular cartilage (Brighton et al. 
2006; Brighton et al. 2008), introduced the inflammatory mediator interleukin-1β 
into some of the cartilage cultures to simulate a disease state. Results showed that the 
electrical stimulation effectively inhibited the upregulation of metalloproteinases 
induced by the interleukin-1β. While these studies focused specifically on how 
cartilage explants  responded to stimulation, the results provide the basis for an 
hypothesis that electrical stimulation may decrease pain by modulating inflammatory 
mediator activity.   
1.3.3   Summary 
Osteoarthritis is a heterogeneous disease in which the processes of pain production 
and perception of pain are very complex. There is conflicting evidence regarding the 




relationships between the pathology and severity of the disease and pain perception. 
Irrespective of this discordance, there are clearly mechanisms whereby pain 
pathways may be influenced by electrical stimulation at a very local level in the 
periphery and this provides support for using electrical stimulation treatment at sub-
sensory intensity.  
1.4  Functional ability and quality of life  
Pain is clearly a prominent clinical feature that is of significant concern to patients 
with OAK. It is also an important determinant of disability (McAlindon et al. 1993; 
Sharma et al. 2003; Torres et al. 2006; Somers et al. 2009). However, it is not the 
only determinant of disability. Similar to pain, there is discordance between disease 
severity measured radiologically, structural progression of OA and functional and 
quality of life (QoL) status (Salaffi et al. 2005; Rosemann et al. 2006; Felson 2009). 
As a consequence, the impact of OAK measured by a person’s ability to carry out 
activities of daily living and participate in social interaction, as well as their general 
well-being, needs to be considered as well as their levels of pain. Indeed, patient 
perception of this impact is central to coping with chronic disease (Patrick and Deyo 
1989; Carr 1999). 
1.4.1   Functional ability and quality of life in the osteoarthritis population 
Both function and QoL are concepts that reflect the health status of an individual or 
population. Limitations in health status contribute to overall disability in patients 
with chronic disease and OA is second only to cardiovascular disease in the western 
world as a cause of disability (Salaffi et al. 2005). 
Functional ability, or perhaps more importantly, functional disability in OA is 
defined in a variety of different ways.  These include describing difficulties with 
mobility and the physical effects of the disease (Maly et al. 2006; Rosemann et al. 
2006; Dunlop et al. 2008) as well as its impact on a combination of work-related, 
recreational, social and self-care activities (Carr 1999; Cieza et al. 2009).  
Osteoarthritis of the hip and knee frequently leads to considerable difficulty with 
mobility tasks such as walking and climbing stairs (Creamer et al. 2000; Felson et al. 
2000) and greater dependence on family and friends for assistance with activities of 
daily living (Guccione et al. 1990; March and Bagga 2004). Jinks et al. (2002) 
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reported that a decrease in functional capacity measured on WOMAC was associated 
with increasing chronicity of disease. Functional disability of this magnitude has 
significant consequences for independent living in an ageing population (Guccione et 
al. 1990; March and Bagga 2004). 
Quality of life may also be defined in various ways with ambiguity existing in the 
literature as the term is interchanged with ‘health status’, ‘subjective well-being’, 
‘life satisfaction’ and ‘functional disability’ (Hickey et al. 2005). However, it is 
usually interpreted broadly encompassing such aspects as emotional well-being (Carr 
1999; Hickey et al. 2005), relationships between family and friends (Carr 1999; 
Hickey et al. 2005), affect and mood (Ang et al. 2006) and physical ability (Ware et 
al. 2002).  
Data from the generic QoL measurement tool, the Medical Outcomes Study Short-
Form 36 Survey (SF-36) interpretation guide (Ware et al. 2002), show that 
normalised scores for the United States population with OA are consistently lower 
than those in the general United States population. This finding is reflected in the 
Australian population (Lapsley et al. 2001; March and Bagga 2004).  
Carr (1999) reported that the impact of OA on QoL is substantial and needs to extend 
beyond functional disability to include emotional and psychological aspects. As 
important elements of health status and QoL, depressive symptoms and impaired 
psychosocial ability are also reported to be prevalent in the OA population (Creamer 
and Hochberg 1998; Sale et al. 2008). 
Importantly, Maly et al. (2006) compared self-report measures of mobility 
(WOMAC physical function subscale) and QoL (SF-36) and noted that the 
relationship between the WOMAC physical function and SF-36 scores was a 
moderate one. That is, while closely related, difficulties with functional mobility and 
QoL cannot necessarily be interpreted interchangeably. This view is supported by 
other authors (Testa and Simonson 1996; Brazier et al. 1999; Salaffi et al. 2005) who 
also recommended using both disease-specific and generic tools to fully determine 
health status in OA.  




1.4.2   Relationship between pain and disability in osteoarthritis 
There is ample evidence that presence of pain in OA is related to decreasing 
functional ability and diminished QoL (McAlindon et al. 1993; Jordan et al. 1997; 
Creamer et al. 2000; Felson et al. 2000; Ang et al. 2006; Ferreira and Sherman 2007; 
Leveille et al. 2007; Hawker et al. 2008; van Dijk et al. 2010).  
In a large cross-sectional study Ang et al. (2006) reported that there was a strong 
relationship between the severity of chronic pain and both physical and mental 
function measured using the SF-36. Hawker et al. (2008) examined the specific 
nature of pain experienced by people with hip or knee OA. They reported that 
different types of pain experience had different impacts on functional ability and 
QoL. That is, that people seemed to be able to manage a dull, chronic ache pain 
while shorter-lasting, but more intense pain, led to avoidance of both social and 
recreational activities. These results support the importance of optimizing pain 
management strategies in OAK in order to improve function and QoL. The full 
account of the relationship between pain and disability, however, is more complex.   
Ferreira and Sherman (2007) described the mediating influences of social support 
and optimism on pain and well-being in OA. This means that perceptions of pain will 
be affected by both social circumstances and personality. A more optimistic and 
socially supported person with OA is likely to perceive their pain as less severe than 
someone who is socially isolated or more pessimistic in outlook independent of 
disease severity.   
Other clinical features such as quadriceps  and other muscle weakness (McAlindon et 
al. 1993; Slemenda et al. 1997; van Dijk et al. 2010), joint malalignment (Sharma et 
al. 2001), decreased joint range of motion (van Dijk et al. 2010), joint laxity and poor 
proprioception (Sharma et al. 2003), and BMI (Creamer et al. 2000; Sharma et al. 
2003) are also important determinants of physical function and disability in OAK. 
Additionally, psychosocial aspects such as anxiety, depression, fear-avoidance 
attributes and lack of confidence in one’s self-efficacy contribute substantially to 
disability in OAK (Creamer et al. 1999; Marks 2007). Importantly, these are also 
reported as determinants of and risk factors for pain in OAK.  
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It is also of interest to consider the bidirectional association between disability and 
OA features (Rosemann et al. 2008). That is, to what extent does decreasing 
functional ability contribute, for example, to pain, muscle weakness and depression 
thus creating a cyclical process of deteriorating health status?  
1.4.3   Summary 
The relationships between pain, pathological features of OAK, function, QoL and 
joint disease are complex. This means that when investigating the effectiveness of an 
intervention, a singular focus on just one of these dimensions is unlikely to deliver a 
comprehensive understanding of a person’s condition. As such, during such 
investigations,  it is essential that outcome measurements are meaningful to patients 
(Bijlsma 2005) and span a range of parameters. Consequently, the achievement of a 
combined improvement in pain, physical function and QoL should be sought. In 
other words, if a treatment improves pain but has significant side effects, is arduous 
to implement, or has negative consequences for general well-being it is less likely to 
achieve compliance with use. The impact that OAK has on function and QoL in an 
ageing population (March and Bagga 2004; Salaffi et al. 2005) means that measuring 
these aspects is essential. 
1.5  Physical activity 
Physical activity is widely acknowledged as being beneficial to good health and 
well-being (Macera et al. 2003; Cress et al. 2004; Haskell et al. 2007; Hunter and 
Eckstein 2009), as well as in slowing down the progress of disability in the elderly 
(Miller et al. 2000). In 1995, the Centers for Disease Control and Prevention and the 
American College of Sports Medicine, issued a consensus expert opinion statement 
recommending that every adult in the United States should accumulate 30 minutes or 
more of moderate-intensity physical activity on most, preferably all, days of the 
week in order to promote health and well-being (Pate et al. 1995). A more recent 
update of this recommendation for healthy adults (Haskell et al. 2007), a companion 
paper with recommendations targeting older adults (Nelson et al. 2007), and a 
physical activity guide for older Australians that incorporates the previously cited 
American recommendations (Brown et al. 2008) have continued to highlight the 
health benefits associated with physical activity.  




Additional recommendations arising from the 2002 Exercise and Physical Activity 
Conference gave clear guidelines for aerobic exercise and neuromuscular 
rehabilitation for people with OAK (Minor et al. 2003). These recommendations, 
again based on consensus expert opinion, stated that people with OA of the hip and 
knee should accumulate 30 minutes of moderate intensity physical activity or 
exercise on at least three days per week as well as undertake combined 
strengthening, endurance, coordination/balance and functional exercise.  
1.5.1   Defining physical activity 
Physical activity is a broad concept that provides challenges for its accurate 
measurement. Caspersen et al. (1985) define physical activity as any bodily 
movement produced by skeletal muscles that results in energy expenditure (p.126). 
Three dimensions: frequency, duration and intensity are often used to enhance this 
definition (Macera et al. 2003). Exercise, a subcategory of physical activity, is 
considered to be more planned, structured and purposeful and aimed at improving 
fitness levels (Caspersen et al. 1985; Macera et al. 2003). Physical activity, while in 
some ways overlapping with, also needs to be considered separately from function, 
where movement is considered in the context of serving a specific task. For example, 
tasks being associated with activities of daily living.  Cress et al. (2004) describe 
physical activity in the context of well-rounded programs in which endurance, 
strength, balance and flexibility are incorporated to enable achievement of general 
health and well-being. Depending on definition, levels of physical activity may be 
measured and interpreted in a variety of ways. For the purposes of this thesis, the 
definition put forward by Caspersen et al. (1985) is used as it more accurately 
reflects the usual physical activity likely to be undertaken by a cohort of people with 
OAK at work and during household and leisure time. 
1.5.2   Physical activity in the osteoarthritis population 
To compare levels of physical activity in a group with OAK and a matched group 
without OAK, Bennell et al. (2004) used a self-report survey, the Human Activity 
Profile (HAP).  The HAP is a self-report questionnaire comprising 94 statements 
relating to whether a person continues to do an activity, has stopped performing the 
activity or has never done the activity (Fix and Daughton 1988). The higher the 
score, the more active the respondent is. Two scores are calculated. The maximal 
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activity score (MAS) represents the highest oxygen-demanding activity the 
participant is still able to perform. The adjusted activity score (AAS) provides a 
reflection of an individual’s typical daily physical activities. The AAS also provides 
a descriptor for activity classification (Fix and Daughton 1988). Participants whose 
AAS is less than 53 are classified as impaired, those with AAS in the range of 53 
to74 are moderately active and those with AAS greater than 74 are classified as 
active. 
There was no difference found in MAS scores between the two groups studied by 
Bennell et al. (2004). However, there were significant differences between the 
groups based on their AAS with the group with OAK being generally less active than 
the control group without OAK.  
In a large epidemiological study using a self-report survey and including all people 
with doctor-diagnosed arthritis of any sort, Shih et al. (2006) reported that people 
with arthritis are less physically active than those people without arthritis. These 
findings reflect those found by Bennell et al. (2004) in the OAK population. 
Farr et al. (2008) measured physical activity levels in 255 patients with early OAK 
and low mean pain scores (88.5 ± 72.2 out of a possible 500) using an accelerometer 
worn for at least eight hours per day for at least six consecutive days. Seventy 
percent of patients did not meet the minimum level of physical activity required to 
enhance health outcomes in adults as recommended by Pate et al. (1995). More 
importantly, 62% failed to meet the Exercise and Physical Activity Conference 
recommendations specifically formulated for people with OAK (2003).  
1.5.3   Joint pain, function and physical activity 
Joint pain is considered a major determinant of physical activity levels with 
increasing pain leading to decreasing activity (van Dijk et al. 2010). It is also the 
most significant correlate with exercise adherence (van Gool et al. 2005). Shih et al. 
(2006) reported a significant association between presence of severe pain and 
inactivity in men. While not reaching significance, there was also a definite trend 
towards this relationship in women. Conversely, engagement in physical activity and 
exercise is reported to improve pain and function in people with OA (Roddy et al. 
2005; Roddy et al. 2005; van Gool et al. 2005; Dunlop et al. 2008) and is 




recommended in clinical guidelines as an important treatment option for managing 
OAK (Vignon et al. 2006; Conaghan et al. 2008; March et al. 2010; Pisters et al. 
2010; Zhang et al. 2010).  
Physical inactivity in people with OA is also associated with the development of co-
morbidities such as muscle de-conditioning and obesity (Shih et al. 2006), while a 
lack of regular vigorous physical activity is a major predictor in worsening levels of 
function (Dunlop et al. 2005). 
1.5.4   Summary 
Despite general consensus regarding the benefits of physical activity, people with 
OAK undertake less physical activity than recommended and thus remain at risk of 
developing co-morbidities. Compliance with structured physical activity programs is 
low despite the longstanding activity level recommendations, specific targeting of 
activity in treatment management plans, and evidence regarding the healthful 
benefits of exercise.  Consequently, physical activity measurement is another 
important parameter to consider when investigating the effectiveness of interventions 
that target pain as a treatment strategy. 
1.6  Rationale for thesis 
The burden of OA in the community is high (Felson et al. 2000; Walker-Bone et al. 
2000; Symmons et al. 2003; Woolf and Pfleger 2003; Buckwalter et al. 2004; 
Buckwalter and Martin 2006; Sharma et al. 2006). With healthcare costs also high it 
is essential that cost-effective options for disease management are explored (Segal et 
al. 2004). The published reports concerning PES for OAK (Zizic et al. 1995; Farr et 
al. 2006; Mont et al. 2006; Garland et al. 2007) suggest that it has the capacity to 
provide a low risk (adverse skin reactions notwithstanding), cost-effective treatment 
option for OAK that could be implemented more widely than it currently is. 
Consequently it was felt that a longer duration, independent investigation into its 
effectiveness was warranted. In order to achieve this, preliminary work was 
conducted in order to develop the protocol for a RCT. The following sections 1.6.1 
through 1.6.7 describe the detailed rationale for the RCT protocol. 
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1.6.1   Study design 
A randomised, placebo-controlled repeated measures trial conducted over 26 weeks 
using valid and reliable outcome measures to evaluate the effectiveness of pulsed 
electrical stimulation (E-PES) was planned.  
The E-PES trial was designed to ensure a valid, unbiased assessment of the 
effectiveness of PES. Key methodological criteria such as independent 
randomisation processes, allocation concealment, a priori power calculations, 
adequate and maintained blinding using a robust placebo, and sufficient follow-up 
(Guyatt et al. 1993; Herbert 2000; Nuesch et al. 2009) were included. Having one 
investigator dealing with all participants through all stages of the study was planned 
to eliminate any bias associated with different clinical styles. Additionally the full 
trial protocol was published (Fary et al. 2008). 
The study design ensured that reporting of results would conform to the Consolidated 
Standards of Reporting Trials (CONSORT) statement (Begg et al. 1996; Moher et al. 
2001) and comply with the recommendations of the Outcome Measures in 
Rheumatology Clinical Trials (OMERACT) group for phase III clinical trials of less 
than one year duration (Bellamy et al. 1997). This meant the inclusion of pain, PGA 
and function in the outcome measures. Additional outcome measurements of joint 
stiffness, QoL, physical activity and an overall perception of improvement were also 
considered to be important inclusions. All outcome measures had previously been 
reported to be reliable and valid in a population of people with OAK. 
Repeated outcome measure assessments were planned to occur at baseline, four, 16 
and 26 weeks. These time frames were chosen to include the only previously 
published RCT time frame (four weeks) available during the thesis development 
stage (Zizic et al. 1995). Sixteen weeks was then planned as the intermediate time 
point as it gave a more even distribution of data collection throughout the trial. 
Participants were to be included if they had a diagnosis of osteoarthritis confirmed 
using the ACR modified clinical classification system (Altman et al. 1986). For 
diagnosis of OAK, this classification requires that a patient experiences knee pain 
and, in addition, presents with four of the following six criteria: aged over 50 years; 
stiffness that lasts for less than 30 minutes in the morning; crepitus on knee joint 




movement; bony tenderness; bony enlargement; and no palpable warmth. The ACR 
modified clinical classification method of diagnosis has a specificity of 89% and a 
sensitivity of 84% (Altman et al. 1986) compared with the combined clinical 
radiographic classification where specificity is 86% and sensitivity 91% (Altman et 
al. 1986).  
Additionally, for inclusion in the E-PES trial, pain had to have been persistent and 
stable for the previous three months.  This was defined as not getting worse or better 
overall despite short-term fluctuations. The three month prior time-frame was chosen 
as it ensured that the study was not biased toward recruitment of patients who were 
either progressively improving or deteriorating with respect to pain intensity. The 
third inclusion criterion was a minimum baseline score on the pain VAS of 25mm. 
This allowed for any achievement of a clinically relevant improvement of 20mm 
(Pham et al. 2004; Tubach et al. 2005) to be accurately measured and reported. 
Participants were to be excluded if they presented with co-existing inflammatory 
arthropathies as this could have confounded the results; contraindications to 
electrical stimulation as the device could not be used; skin disorders in the vicinity of 
the knee to be treated so that any adverse skin reaction would be recognised and 
attributed to use of the device; a TKR scheduled during the study period as that 
would introduce a contraindication to device use and confound the results; and/or 
insufficient English to follow instructions and complete forms as all outcome 
measures other than accelerometers were to be paper-based. For maintenance of safe 
device use it was vital that participants were able to fully understand the written 
instructions.  
Statistical analysis was planned to report outcomes of clinical significance to ensure 
that any results were meaningful to patients. Ethical approval from the Curtin 
University Human Research Ethics Committee was sought and approved 
(HR122/2006) and the trial was registered with the Australian Clinical Trials 
Registry (now Australian and New Zealand Clinical Trial Registry, 
12607000492459) prior to commencement. 
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1.6.2   Measurement of pain 
The primary outcome of the E-PES trial was chosen to be change in pain measured 
on a 100mm VAS over 26 weeks (Appendix 5a). The reliability of the VAS has 
previously been demonstrated (Melzack and Katz 1999) and it is regularly used in 
research studies in this population.  
An incidental measurement of pain was also included with the use of the full 
WOMAC Likert format 3.1 questionnaire (Appendix 5e). The WOMAC is a disease-
specific, self-administered measure of health status assessing pain, stiffness and 
function. Higher scores denote worse health status. The WOMAC Likert format 3.1 
for pain has a maximum score of 20. It is a valid and reliable tool for use in this 
population (Bellamy 2004). 
Pain was to be measured at baseline, four, 16 and 26 weeks. 
1.6.3   Measurement of patient global assessment 
This outcome measure asks a patient to consider how their condition is affecting 
them at the time of assessment. That is, it is a time-specific outcome measure. The 
PGA chosen for use in this study was a 100mm VAS described by Ehrich et al. 
(2000) (Appendix 5a). Respondents were to consider all the ways in which their 
arthritis was affecting them at each data collection point. The left hand anchor of the 
VAS was marked as Very Well and the right hand anchor as Very Poorly. 
Patient global assessment was to be measured at baseline, four, 16 and 26 weeks. 
1.6.4   Measurement of health status - function and quality of life 
As reported beforehand, the inclusion of separate measures for functional ability and 
QoL was warranted to give a more comprehensive assessment of health status.  
WOMAC is recommended by OMERACT as the instrument of choice for measuring 
function in OA of the lower limbs (Bellamy et al. 1997). WOMAC Likert format 3.1 
was chosen for use in this study (Appendix 5e). A maximum score of 68 is available 
from answering the 17 questions about functional ability with higher scores 
reflecting worsening function. 




The total WOMAC score, an aggregation of pain, stiffness and function scores 
(maximum 96), provides a disease-specific measure of health status for people with 
OA of the knee or hip. However, it does not provide information about the social or 
emotional consequences of the disease.  
The SF-36 has eight subscales reflecting both physical and mental health status as 
well as two physical and mental component summary measures (Appendix 5b). 
Comprised of 36 questions it is, like the WOMAC, a self-administered questionnaire. 
It is a well studied, valid and reliable outcome measure that has become a valuable 
tool as a generic, rather than disease-specific, measure of disease burden (Ware 
2000; Ware et al. 2002). It is widely used and considered a valid psychometric tool in 
OA studies (Kosinski et al. 1999). Raw scores for each subscale and the two 
summary measures are normalized to scores out of 100 where higher scores reflect 
better general well-being and a score of 50 is the general population mean. 
There are limitations to using only self-report methods when measuring some 
variables. Stratford and Kennedy (2006) and Maly et al. (2006) report that pain 
change is the most important determinant of change in self-reported function with the 
WOMAC. Stratford and Kennedy (2006) state further that progress measured with 
WOMAC is often not reflected by actual performance measures post arthroplasty. 
This is supported by Maly et al. (2006) who found that self-report and performance 
measures seem to measure different things in people with OAK. Additionally, 
Stratford et al. (2003) advise that clinicians and researchers need to consider closely 
the tool for measuring function to ensure that the right tool is used in the right 
circumstance. For example, if the goal for task achievement requires particular 
timing for completion then performance measurement would be better than self-
report. Conversely, Steultjens et al. (1999) report that very similar information is 
gained when using both self-report and performance measures and state that 
consideration needs to be given to what is to be gained with the different measures.  
Later work by Steultjens et al. (2001) demonstrated, in a cohort of people with OA of 
the hip or knee, that there was no difference between responsiveness of self-report 
measures of disability and of performance measures. Further they added that because 
of the advantages of using questionnaires (ease of use, time-effectiveness and 
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minimal subject burden) over extended performance based measures, self-report 
outcome measures were preferable.  
In deciding which specific outcome measures to use, the substantial commitment 
required of participants during a 26 week trial was considered an important factor. 
Additionally, it is acknowledged that pain and perception of pain improvement is 
critical to patients (Patrick and Deyo 1989).  These two factors combined with the 
work of Steultjens et al. (1999; 2001) led to the decision that use of self-report 
measures alone for function and QoL was appropriate.  
Both WOMAC and QoL were to be measured at baseline, four, 16 and 26 weeks. 
1.6.5   Measurement of joint stiffness 
As the WOMAC health status instrument was being used for pain, function and 
overall health status, it was decided that its third component, joint stiffness, should 
also be measured at the same times and reported independently. The maximum score 
for stiffness is eight (Appendix 5e). 
1.6.6   Measurement of physical activity 
Accelerometers provide an accurate, objective measurement of ambulatory physical 
activity (Ainsworth and Coleman 2006), are recommended for use in physical 
activity research (Ward et al. 2005) and have been validated for use in the older 
population (Brandon et al. 2004). However, they have their limitations. They are 
relatively expensive and require equipment and software to support their use 
(Ainsworth 2009). They do not measure activities such as swimming or bicycling, 
nor do the dual-axis versions distinguish between steps taken up a flight of stairs and 
those taken on level ground. Additionally, Hendelmann et al. (2000) report that 
accelerometer count data and metabolic equivalent (MET) calculations may not 
correlate very well as  upper body use and load carriages are underestimated. 
Therefore, while providing a direct measurement of ambulatory activity, the 
accelerometer may underestimate the amount of health enhancing activity that people 
are engaging in. 
Self-report questionnaires are also commonly used to measure physical activity, are 
often valid and reliable, and are often the method of choice in large scale 
epidemiological studies (Fix and Daughton 1988; Brown et al. 2004; Ainsworth and 




Coleman 2006; Shih et al. 2006). Whilst inexpensive and easy to use, they are also 
subject to recall bias and require a certain degree of literacy on the part of the person 
completing the questionnaire. Vigorous activity is likely to be overestimated by 
questionnaires while activities of daily living more likely to be underestimated 
(Ainsworth 2009).  
For the E-PES trial, both accelerometer (Actigraph GT1M) and self-report (HAP) 
(Appendix 5d) data were to be collected at baseline and 16 weeks. Participants were 
to wear their accelerometers, held secure in a nylon pouch positioned over the 
anterior superior iliac spine, on a belt around their waist during waking hours for 
eight consecutive days. This duration was to ensure collection of six full days of 
data. Accelerometers were to be taken off only for showering and water-based 
activities.  A data reduction program developed by the Actigraph manufacturer was 
to be used to determine the number of minutes spent per day in four categories of 
activity intensity level (resting, light, moderate and vigorous). The cut off points for 
these categories described by Swartz et al. (2000) were chosen as they more closely 
reflected usual daily activity tasks in this population. 
Resource constraints meant that collecting follow up physical activity data at 
multiple time points was not possible. Consequently, sixteen weeks was chosen as it 
was considered that fewer people would have dropped out at 16 weeks than at 26 
weeks thus giving access to larger numbers for analysis. 
1.6.7   Measurement of overall perceived improvement 
Measuring individual aspects of disease presentation is necessary to tease out 
relationships that may exist between each parameter and to provide a more complex 
overview of an intervention’s effectiveness. However, it is also essential to ascertain 
how each person feels about their overall progress. For this reason, the global 
perceived effect scale (GPES)(Appendix 5c) was included in the array of outcome 
measures to be used in this thesis.  
The GPES was to give participants the opportunity of saying whether they felt better, 
the same or worse by varying degrees since entering the study. An 11-point scale as 
reported by Pengel et al. (2004) ranging from -5 (vastly worse) to +5 (completely 
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recovered) with zero point being unchanged was chosen to be administered at both 
16 and 26 weeks. 
1.6.8   Thesis plan  
The preliminary work conducted to prepare for the E-PES trial forms the content of 
Chapters 2, 3 and 4. Chapter 2 describes, by way of published paper (Fary et al. 
2009), a pilot study conducted to ensure familiarity with equipment use, provide 
experience with subject recruitment and retention in the study, assist with the E-PES 
trial protocol development, and develop an understanding of outcome measures, 
equipment use compliance and any adverse effects from its application. This study 
used the commercially available Bionicare® BIO-1000™ device. 
Equipment was a crucial component of this thesis. Initial negotiations with the 
BioniCare Medical Technologies Inc. to use the Bionicare® BIO-1000™ device and 
the placebo equipment used in the previous RCTs (Zizic et al. 1995; Garland et al. 
2007) were positive. However, changed financial circumstances of the company 
meant that by the time this trial was to commence, the equipment was no longer 
available. Chapter 3 describes the equipment development process undertaken to 
ensure equipment was available to continue with this research. A positive 
consequence of this situation was that the E-PES trial would be conducted completed 
independently of commercial interests. Additionally, some concern had been 
expressed by BioniCare Medical Technologies Inc about the robustness of its 
placebo device. Developing our own equipment meant that this concern could be 
addressed as well. 
Chapter 4 describes, by way of paper, E-published ahead of print (Fary and Briffa 
2010), the process undertaken for and the results of testing the new equipment 
developed. It provides clear support for the type of current chosen for investigation 
in the main study of this thesis. 
The published protocol for the E-PES trial (Fary et al. 2008) is the subject of the fifth 
chapter.  
Chapter 6 describes, by way of paper submitted, the results of the E-PES trial. 




Finally, chapter 7 provides a summary of the thesis, a discussion of its main findings 
and the significance and clinical implications of these findings. 
Supporting documentation not available in the forthcoming chapters is available in 
the following appendices. 
Appendix 1: Participant information forms  
Appendix 2: Participant informed consent forms  
Appendix 3: E-PES trial administrative checklist 
Appendix 4: E-PES trial telephone screening form  
Appendix 5: Paper-based outcome measure forms  
Appendix 6: Instructions for use of PES equipment  
Appendix 7: Medication and hours of use diaries 
1.7  Summary and significance 
As a non-pharmaceutical, non-invasive, relatively inexpensive modality with few 
reported side effects, PES has the potential to provide an effective, more widely used 
treatment option for OAK, a condition presenting a substantial worldwide health 
burden. The previous studies into the modality cited in this literature review were all 
conducted with support from, and by several employees of, the manufacturers of the 
commercially available product Bionicare® BIO-1000™ , BioniCare Medical 
Technologies Inc. (Zizic et al. 1995; Farr et al. 2006; Mont et al. 2006; Garland et al. 
2007). As a consequence, these studies were open to bias and conflict of interest. The 
two RCTs of four and 12 weeks were also relatively short-term (Zizic et al. 1995; 
Garland et al. 2007).  
The purpose of this thesis is to provide an independent, long-term evaluation of the 
effectiveness of PES for managing symptoms of OAK. Specific aims were to 
determine the influence of PES on pain, function, QoL, physical activity levels and 
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Chapter 3: Development of pulsed electrical stimulation 
equipment 
3.1   Introduction 
When developing the project for this thesis BioniCare Medical Technologies Inc., the 
company that produced the BioniCare  BIO-1000TM  used in the previous chapter’s 
pilot study (Fary et al. 2009), expressed considerable interest in providing the 
equipment for the ongoing research. So much so that in early January, 2007, written 
confirmation of support, by way of equipment provision for the project, was 
received. By March that year, the financial circumstances of the business had 
changed meaning that the equipment was no longer available for use. As no other 
commercially available devices contained the specific parameters described by the 
previous PES reports (Zizic et al. 1995; Farr et al. 2006; Mont et al. 2006; Garland et 
al. 2007), it was necessary to develop our own equipment with these parameters. 
While this added a substantial extra component to the thesis, it also resulted in a 
study conducted completely independent of commercial concerns. This can only be 
seen in a positive light.  
Research conducted under the auspices of commercial entities may be open to bias 
and conflict of interest (Wynia and Boren 2009). Meta-analyses comparing results 
from industry-funded drug trials with those conducted without industry funding have 
shown that there are substantially increased odds of finding favourable results in 
reports from industry-funded research (Bekelman et al. 2003; Lexchin et al. 2003). 
The E-PES trial protocol associated with this thesis incorporated key research 
elements to reduce bias. Nevertheless, had it remained supported by a commercial 
entity, perception of bias or conflict of interest may have existed. Being completely 
independent meant that this perception would be eliminated and is one of the 
strengths of the study. 
Verbal communication with BioniCare Medical Technologies Inc. had also 
highlighted some concern with the placebo device used in the Garland et al. (2007) 
and Zizic et al. (1995) RCTs. It was stated that while the current flow cut out after 
three minutes, it could easily be restarted by unlocking the device and turning up the 




intensity. This could potentially have led to people in the placebo group receiving 
more than the three minutes of stimulation intended if they were to adjust the 
intensity during the treatment duration. Developing our own equipment meant that 
this concern could also be addressed. 
The Department of Medical Technology and Physics at Sir Charles Gairdner 
Hospital in Nedlands, Western Australia, was approached to source the expertise 
required for the development of the PES equipment and a robust placebo device. As 
a result, Senior Biomedical Engineer, Mr Chris Tingley, provided advice, the 
technical expertise, practical application and safety assurances to produce the 
equipment for the study.  
3.2  Choice of equipment 
Commercially available TENS units were chosen for modification as they provided 
convenient casing and controls and were similar in size to the BioniCare  BIO-
1000TM  units. They were also readily available without prescription and relatively 
inexpensive to purchase.  
Initially the Metron Pro-10s unit (Ausmedic Australia, Hilton, WA Australia) was 
chosen as it provided a continuous treatment option and a physical guard over the 
control dials to prevent inadvertent changes to intensity or waveform parameters. 
Unfortunately it did not offer a 100Hz frequency and even with alternative 
commercially available crystals (electronic resonators that set frequency) substituted 
into the electronic circuit, the closest frequency obtainable was 94Hz.  
The Metron Digi-10s (Ausmedic Australia) was then investigated as a possible 
alternative. This unit was slightly more expensive but had the advantage of having a 
digital display of parameters, a locking button to ensure no inadvertent changes to 
intensity or treatment parameters occurred, and was able to deliver an exact 
frequency of 100Hz. It also provided a continuous treatment option which was 
necessary for prolonged treatment duration. 
 
 





3.3  Electrical stimulation waveforms 
The electrical parameters of the BioniCare  BIO-1000TM  are described by Zizic et al. 
(1995) as pulsed, monophasic current with a frequency of100Hz, and a spiked, 
exponentially decreasing wave form. These parameters were replicated within the 
Metron Digi-10s casing. 
This was achieved by inserting a diode into the circuit to cut off half of the existing 
biphasic current wave form. Unfortunately, early testing of this device produced 
unacceptable, significant, adverse skin responses under the electrodes. This was 
unexpected given it was an exact replication of the Zizic et al. (1995) current and 
adverse skin reactions were not a major feature in the BioniCare  literature. However 
skin irritation and even chemical burns are considered common side effects of 
monophasic current (Hooker 2001) so in that context, the adverse skin reactions 
occurring were not that surprising.  
Subsequent to this early testing of the monophasic current, another prototype was 
developed. The BioniCare  BIO-1000TM wave shape, pulsed nature and frequency 
parameters were maintained but instead of a monophasic current type, an 
asymmetrically biphasic current type was incorporated (Figure 3.1). Because of the 
alternating flow of current with a biphasic waveform there is less likelihood of a 
chemical build up occurring under the electrodes and therefore less likelihood of 
adverse skin reactions. Early attempts to produce the desired waveform caused the 
device to draw too much current from the battery for the intended durations of use. 
Through experimentation it was found that a small 0.47ufd capacitor installed into 
the output circuit would produce the correct waveform without consuming excessive 
battery power.  
3.4  Placebo device 
The placebo device was constructed to also produce the asymmetrically biphasic 
wave form. This ensured that in the initial stage of turning on and setting the device, 
the same type of current was delivered to all participants. Doing so was to protect 
blinding within the study as the overall sensation produced by the current would be 
the same for all participants. An additional three-dimensional, three minute timing 
component was developed for insertion into 35 of the devices (Figure 3.2).  




The timing component cut off the electrical stimulation after three minutes to 
replicate the time used in the placebo in the RCTs by Zizic et al. (1995) and Garland 
et al. (2007). By then the treatment was being delivered at the sub-sensory intensity 
so the participants were unaware that the current flow had stopped. There was no 
change to the liquid crystal display (LCD) screen so the device still appeared to be 
delivering current flow. Unlike the BioniCare Medical Technologies Inc. placebo 
device, current could not be recommenced by simply adjusting the intensity of the 
current flow up. The whole device needed to be turned off and then back on again. 
This meant that the possibility of regularly receiving bursts of PES treatment was 
eliminated. 
 
Figure 3.1 Asymmetrically biphasic experimental waveform as viewed on the 
oscilloscope through 500 ohms resistance 
 
Figure 3.2 Placebo circuit 





3.5  Electrodes and mechanism for capacitive coupling 
Consistent with the aim of replicating previous reported use of PES, the method of 
application was also replicated. Neoprene wraps based on the wrap-around, three 
point Velcro securing system used with the BioniCare  devices were manufactured 




Figure 3.3 PES equipment as used by participants 




Colour-coded Velcro anchors (red and black) were stitched to the inside of the wrap 
to ensure constant electrode placement (Figure 3.4). 
 
Figure 3.4 Neoprene wrap showing colour-coded Velcro attachments, electrodes, 
electrode pockets, electrode wires and PES control box 
 
 
Figure 3.5 Neoprene wrap with electrode pockets attached internally via Velcro 





Multiple use, conductive, silicone electrodes measuring 120 mm long and 80 mm 
wide were used. These were chosen rather than self-adhesive ones because of the 
duration of skin contact with treatment and cost. This size of electrode was the 
largest available at the time yet it was still smaller than the flexible electrodes used in 
the BioniCare® system. 
Electrode pockets made of calico material and measuring 175 mm long and 100 mm 
wide were made to extend the area of the electrical field (Figure 3.5). This size 
closely resembled the size of electrodes used in previous studies. Additionally, 
impedance testing demonstrated that increasing the size of the electrode contact 
surface decreased the impedance. This in turn decreased the electrical field density at 
the skin-electrode interface – an important factor to consider with the treatment 
duration proposed. 
3.6  Coupling gel 
As previous PES studies had concluded that adverse skin reactions were likely to be 
caused by response to conductive gel (Zizic et al. 1995; Garland et al. 2007), a salt 
free hypoallergenic gel, Spectra 360 (Parker Laboratories Inc., Fairfield, New 
Jersey, USA), was chosen for this study.  
3.7  Batteries 
Rechargeable batteries were used because the duration of treatment time (minimum 
of seven hours per day) meant that it was both economically and environmentally 
unfeasible to use non-rechargeable batteries. 
Early biphasic waveform development attempts drew current from the battery at a 
rate of 50 milliAmps/hour (mA/h). This meant that a battery would need a capacity 
of at least 350mA to be able to provide power for the seven hours required and that 
even with high capacity batteries, the current draw needed to be reduced. By altering 
the way the wave form was produced, that is by inserting the 0.47ufd capacitor, the 
current draw was reduced to a maximum rate of 20 mA/hour. 
 
 




Rechargeable, Powerex brand, 9 volt, nickel metal hydride batteries (Maha Energy 
Corp., City of Industry, California, USA) with a capacity of 300 mA hours were 
sourced for the study (Figure 3.6). A bench test of these batteries was conducted 
using the experimental PES device at a discharge rate of 20 mA/h across a resistance 
of 1,000 Ohms. Results demonstrated that the battery would continue to provide 
enough power for continuous treatment for up to nine and a half hours. This was 
clearly sufficient for the study requirements.  
 
3.8  Instruction manual 
An instruction manual was developed so that important issues such as a summary of 
the study requirements; warnings about use; what to do should any adverse events 
occur; care of equipment; step by step instructions for use; and contact details for the 






Figure 3.6 Battery and charger 





3.9  Summary 
Having completed the development phase, it was necessary to formally test the PES 
equipment. In particular, the monophasic waveform equipment was to be compared 
with the biphasic one for both adverse skin reaction and comfort. It was anticipated 
that the rate of adverse skin reaction after use of the biphasic prototype would be less 
than that after use of the monophasic one. Additionally, the rates were to be 
compared with those previously cited (Zizic et al. 1995; Farr et al. 2006; Mont et al. 
2006; Garland et al. 2007).  
Results demonstrated that the slightly biphasic current was comfortable to use and 
had an acceptable rate of adverse skin reaction. The rate of adverse skin reaction 
noted after use of the monophasic prototype was unacceptably high. These data are 
presented in Chapter 4 as a paper, E-published ahead of print (Fary and Briffa 2010) 
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produces high rates of adverse skin reactions in healthy subjects. 



































































































































































Chapter 5: The effectiveness of pulsed electrical stimulation 
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effectiveness of pulsed electrical stimulation (E-PES) in the management 
of osteoarthritis of the knee: a protocol for a randomised controlled trial. 







































































































































































































Chapter 6: The effectiveness of pulsed electrical stimulation 
(E-PES) in the management of osteoarthritis of the knee: 






Fary, R.E., Carroll, G.J., Briffa, T.G. and Briffa, N.K. The effectiveness 
of pulsed electrical stimulation (E-PES) in the management of 
osteoarthritis of the knee: results of a randomized controlled trial. As 
submitted to Arthritis & Rheumatism  November  2010.











Objective To determine the effectiveness of sub-sensory, pulsed electrical 
stimulation (PES) in the symptomatic management of osteoarthritis of the knee. 
Methods A double-blind, randomized, placebo-controlled, repeated measures trial in 
70 participants with clinical and radiologically diagnosed osteoarthritis of the knee 
who were randomized to either PES or placebo. The primary outcome was change in 
pain over 26 weeks measured on a 100mm pain VAS. Other measures included pain 
(WOMAC), function (WOMAC), patient global assessment (100mm VAS), joint 
stiffness (WOMAC) quality of life (SF-36), physical activity (Human Activity 
Profile; accelerometer) and global perceived effect (11-point scale). 
Results Thirty-four participants were randomized to PES and 36 to control. Intention 
to treat analysis showed a statistically significant improvement in pain VAS over 26 
weeks (p≤0.001) in both groups, but no difference between groups (mean change 
difference 0.9mm; 95%CI -11.7mm to 12.5mm). Similarly no differences existed 
between groups for changes in WOMAC pain, function and stiffness scores [-5.6 (-
14.9 to 3.6); -1.9 (-9.7 to 5.9); 3.7 (-6.0 to 13.5) respectively], SF-36 physical and 
mental component scores [(1.6 (-1.5 to 4.8) and 1.2 (-2.9 to 5.4) respectively], patient 
global assessment [-2.8 (-13.9 to 8.4)] or activity measures (p > 0.16). 
Fifty-six percent of the PES group achieved a clinically relevant 20mm improvement 
in pain VAS at 26 weeks compared with 44% of controls (95%CI -11% to 33%). 
Conclusion In this sample with mild to moderate symptoms and moderate to severe 
radiographic osteoarthritis of the knee, 26 weeks of PES was no more effective than 
placebo.  
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Electrotherapy is often used to manage symptoms of osteoarthritis (OA). It is a 
relatively inexpensive, non-invasive, short-term treatment option, which is 
recommended in evidence-based clinical guidelines (1-4). One electrotherapy 
treatment, pulsed electrical stimulation (PES), has been reported to significantly 
decrease pain and improve function in knee OA (5-8). Anecdotal evidence however 
and our personal observations suggest that PES is not widely used. 
PES is delivered through capacitive coupling using surface electrodes and 
conduction gel. While often being grouped with transcutaneous electrical nerve 
stimulation (TENS) (9), it does differ from TENS and interferential therapy (IFT) in 
its specific electrical current parameters and its proposed method of action (6). In 
particular, it is delivered at sub-sensory intensity. That sub-sensory electrical 
stimulation is reported to be effective in managing pain suggests a local mechanism 
of action. This mechanism is at present poorly understood. However, there are many 
pain mediating receptors in the periphery that may be affected by an externally 
applied electrical field by virtue of their endogenous electrical potential and the role 
of polarization in receptor function and nociceptor stimulation (10). It is possible that 
externally applied electrical stimulation interferes with this process and thus reduces 
pain perception. 
PES is also reported to be a potential disease modifier through its capacity to up-
regulate chondrocyte activity (11-14). This assertion is yet to be tested in humans, 
mainly because long-term effectiveness and compliance with use has yet to be 
established. 
As OA of the knee is a chronic disorder, we considered the earlier randomized 
controlled trials of PES of four (8) and 12 (6) weeks duration to be relatively short.  




Additionally, Farr et al. (5) in a prospective, longitudinal study referred to a dose-
response relationship suggesting that increasing PES use results in better pain 
management. This assertion has not been tested in an independent randomized 
controlled trial.  
As current treatment options have moderate effect sizes at best (15) and are often 
limited in use by contraindications and co-morbidities (16, 17) we wanted to examine 
whether the reported improvements with PES use continued beyond 12 weeks. By 
doing so we aimed to determine whether PES could provide a useful, low risk 
addition to OA management with a view to studying its potential as a disease-
modifier.  
The primary aim of this study was to determine whether PES decreased pain in OA 
knee over 26 weeks. Other outcomes included function, patient global assessment 
(PGA), quality of life, physical activity and overall perceived effect.  
PATIENTS AND METHODS 
The full protocol of this double-blind, randomized, placebo-controlled, repeated 
measure trial is published elsewhere (18). The trial was approved by the Curtin 
University Human Research Ethics Committee (HR122/2006) and all participants 
gave written informed consent. All recruitment tasks, screening, measurements and 
instructions for use of the device were completed by the same experienced musculo-
skeletal physical therapist (RF).  
Participants 
Seventy participants (mean age 70 years, 53% male) were enrolled between 
September 2007 and April 2009. Diagnosis of OA of the knee was in accordance 
with the American College of Rheumatology (ACR) modified clinical classification 
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system (19). Plain X-rays available for 64 participants confirmed the diagnosis. 
Persistent and stable pain (defined as not getting worse or better overall despite 
short-term fluctuations) for a minimum of three months prior to study entry was 
confirmed in all participants by phone interview. All participants had a baseline pain 
score of at least 25mm on a 100mm visual analogue scale (VAS).  Volunteers were 
excluded if they had co-existing inflammatory arthropathies; contraindications to 
electrical stimulation; skin disorders in the vicinity of the knee to be treated; total 
knee replacement scheduled during the study period; and/or insufficient English to 
follow instructions and complete forms. 
Recruitment occurred through notices in published newsletters of community 
organizations, letters to medical general practices and word of mouth. Data were 
collected in person at the University and by mail.  
Randomization and blinding 
Allocation, stratified by gender, age (<60, 60-75 and >75 years), and baseline VAS 
pain scores (25-40, 41-60 and 61-100mm), was performed independently by an 
administrator, not otherwise involved in the study, using computer generated 
randomisation in blocks of six. Following the randomization process, the 
administrator provided the serial number of an appropriate device (placebo or active) 
and the device was then dispensed to the participant. This process ensured that all 
study investigators and participants remained blind to allocation until analysis was 
complete. 
Intervention 
A commercially available TENS stimulator (Metron Digi-10s) was modified by a 
biomedical engineer to deliver PES current parameters as follows: pulsed, 




asymmetrically biphasic, exponentially decreasing waveform with a frequency of 
100Hz and pulse width of 4ms. Current was delivered via 120 x 80mm multiple use 
conductive silicone electrodes inserted into larger calico pockets (175 x 100mm) to 
increase the contact surface area and reduce current density. Electrodes, positioned 
over the anterior distal thigh (anode) and anterior to the knee joint itself (cathode), 
were coupled to the skin using hypoallergenic conduction gel and secured with 
specially made neoprene wraps.  The placebo device was identical in appearance and 
method of use, however, the current flow was programmed to turn off after three 
minutes. Being a sub-sensory treatment, this change was not detectable by 
participants. 
Identical written instructions were provided to all participants.  They were asked to 
wear the device seven hours daily, preferably overnight, for 26 weeks. Specifically, 
participants attached the device and turned the intensity up until they could feel pins 
and needles or a prickling sensation under one or both electrodes. After achieving 
sensory output, participants were instructed to turn the intensity down until they 
could no longer feel any electrical stimulation. At this stage a built in locking 
mechanism that prevented subsequent adjustment of intensity without restarting the 
device was engaged.  
Participants kept a log (hours) of device use over 26 weeks. At exit, they were asked 
to indicate whether they thought their device was PES or control.  
Background therapy 
Participants were advised to continue their usual treatment for OA throughout the 
study, including prescribed medications, health professional interventions such as 
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exercise programs, and complementary therapies. However, they were counseled 
against starting any new treatments. A medication diary was kept by all participants. 
Outcome measures 
The primary outcome was change in pain over 26 weeks measured on a 100mm pain 
VAS. Participants responded to the following instruction: Consider the amount of 
pain that you have experienced due to arthritis in your treated knee over the past 48 
hours. Please make a vertical mark crossing the line below at a point that you 
consider indicates how severe your pain has been. The left side anchor of the line 
was marked as no pain and the right side anchor as extreme pain. 
In addition, physical function (Western Ontario and McMaster Universities 
Osteoarthritis Index [WOMAC] Likert format 3.1) and PGA (100mm VAS (20)) 
were measured to complete the core set of three primary efficacy variables, 
recommended by the Outcome Measures in Rheumatology Clinical Trials 
(OMERACT) group (21). Administration of the WOMAC provided an incidental 
pain score. These outcomes were measured at baseline, four, 16 and 26 weeks. 
Other outcome measures included: quality of life (Medical Outcomes Study 36-item 
Short-Form Health Survey version 2 (SF-36)) and joint stiffness (WOMAC 3.1) 
measured at baseline, four, 16 and 26 weeks; physical activity (Human Activity 
Profile (22) and Actigraph GT1M accelerometers worn for seven consecutive days) 
measured at baseline and 16 weeks; and an 11-point global perceived effect scale 
(GPES) (23) administered at 16 and 26 weeks. 
Two measures of physical activity were administered to enhance measurement 
precision.  The Human Activity Profile (HAP) is a valid and reliable self-report 




questionnaire but is subject to information bias (24). Accelerometers provided a 
direct measure of ambulatory physical activity. 
Licence agreements for the WOMAC 3.1, SF-36 and HAP were obtained pre-study. 
Sample size 
A priori calculations for sample size were based on published pain VAS (6), PGA (6) 
and WOMAC function (25) data. 
 It has previously been proposed that the minimal clinically important improvement 
(MCII) in OA knee pain is 19.9mm on a 100mm pain VAS (26). Further, a change of 
20mm has been defined as the minimum required for classification as a primary 
responder by Osteoarthritis Research Society International (OARSI) (27, 28).  
Accordingly, we deemed that an improvement in the PES group of 20mm greater 
than that achieved in the placebo group would constitute a clinically meaningful and 
important difference.  Allowing for 20% withdrawals, it was determined that a 
sample of 70 would be sufficient to detect a between group difference of 20mm in 
change of pain VAS, as well as differences in change equal to MCII of 9.1 points for 
WOMAC function and 18.3mm for PGA (26). Calculations specified a power of 
80% and a two-tailed test with alpha level 0.05. 
Data analysis 
Analyses were performed on an intention to treat basis using the Statistical Package 
for the Social Sciences, version 17.0. The last-observation-carried-forward method 
was applied for participants who completed at least one set of follow up data. 
Differences between groups at baseline, and changes between baseline and 26 weeks 
were examined using independent t-tests. To test for the fixed effect of treatment, 
repeated measures analysis using a linear mixed model was performed for pain VAS, 
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PGA, WOMAC scores and SF-36 at each follow-up. Between group comparisons of 
GPES scores at 16 and 26 weeks were analysed using independent t-tests. In 
secondary analyses, chi-square was used to compare proportions achieving MCII in 
pain, function and PGA and proportions reporting improvement in GPES scores in 
each group at all follow-ups.  Differences were interpreted as significant if <0.05. 
RESULTS 
Characteristics of participants 
From September 2007 to November 2008, a total of 120 participants were 
provisionally vetted by telephone and 85 given appointments for formal screening 
and baseline assessment where appropriate. Seventy participants were randomized in 
the study (Figure 1). 
Baseline characteristics were comparable between groups with the exception of a 
lower BMI in controls (p=0.04) (Table 1). Of the sample, 37 (53%) were male, mean 
BMI was 28.1 and 48 (69%) had Kellgren-Lawrence radiographic scores of 3 or 4. 
Symptoms were mild to moderate in severity.  Overall, mean baseline pain VAS 
score was 52mm with only 20 (28%) participants scoring above 60 mm. By 
comparison, WOMAC pain scores were generally lower with only five (7%) scoring 
above 60/100 on the normalized scale. WOMAC function scores also suggested low 
levels of disability.  
Participants were physically active with 51 (73%) classified as moderately active or 
active according to their HAP adjusted activity score. Similarly, accelerometer data 
showed the average daily time spent in moderate level activity (3-6 metabolic 
equivalents) exceeded the 30 minutes per day, five days per week recommended by 
Haskell et al (29) to gain health benefits (Table 1). 



































Figure 1. Flow of participants through the trial  
Abbreviations: TKR – total knee replacement, ACR – American College of Rheumatology, PES – pulsed electrical stimulation. 
Call for volunteers 
Assessed for eligibility by 
telephone (n=120) 
Those fulfilling initial 
eligibility criteria attend first 
visit for second and final 
screening (n=85) 
Concealed randomization stratified for age, gender and pain (n=70) 
Excluded (n=35) 
Co-existing inflammatory arthritis (n=4)  
Psoriasis around knee (n=1)  
Did not meet pain criteria (n=9)  
Planned TKR within six months (n=3) 
Transport difficulties (n=2)  
Protocol too difficult (n=8)  
Contraindications to electrotherapy (n=5)  
Personal difficulties (n=2)  
Already using regular electrotherapy on knee (n=1)  
 
Excluded (n=15) 
Did not meet ACR classification (n=1)  
Did not meet pain criteria (n=3)  
Protocol too difficult (n=4)  
Skin too fragile (n=1)  
Failed to attend appointment (n=6) 
Placebo device (n=36) PES device (n=34) 
(n=36) One subject failed to return 
four week data (n=33) 
One subject withdrew 
(unable to comply with 
protocol).  One subject failed 
to complete accelerometer 
data. Full data set (n=34). 
Partial data set (n=35). 
One subject withdrew 
(device uncomfortable) and 
subject who failed to 
complete week 4 data 
returned (n=33) 
(n=35) One subject failed to attend 
final appointment (n=32) 
Analysed (n=36). Intention to 
treat and last measurement 
carried forward. 
Analysed (n=34). Intention to 
treat and last measurement 
carried forward. 
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 Table 1. Baseline characteristics of the participants 
Characteristic (mean (SD)) unless otherwise 
indicated 
Control (n=36) PES (n=34) 
Age (years)  68.9 (11.4) 70.7 (8.9) 
Male gender (%) 56 50 
BMI (kg.m-2) 26.8 (4.3)  29.4 (5.9)  
Duration of symptoms (years) 11.4 (7.8) 12.6 (12.7) 
Time since osteoarthritis diagnosis (years) 9.4 (10.3) 6.9 (7.4) 
Kellgren-Lawrence radiographic grade  (number) †   
1 3  1  
2 5  7  
3 10  14  
4 13  11  
Clinical features of osteoarthritis (number (%))   
Stiffness < 30 minutes in morning 31 (86.1) 30 (88.2) 
Crepitus 33 (91.7) 31 (91.2) 
Bony tenderness 21 (58.3) 25 (73.5) 
Bony enlargement 25 (69.4) 30 (88.2) 
No palpable warmth 36 (100.0) 32 (94.1) 
Osteoarthritis laterality    
Bilateral (%) 47 56 
Right side treated (%) 50 62 
Medication use (number using (%)) ‡   
Complementary (glucosamine and fish oil) 19 (54) 15 (52) 
Analgesic 18 (51) 10 (34) 
Non-steroidal anti-inflammatory 15 (43) 13 (45) 
Pain (VAS mm) 52 (18.2) 51 (17.2) 
Patient global assessment (VAS mm) 47 (24.5) 44 (19.3) 
WOMAC score (all normalized/100)   




Pain subscale  36 (18.1) 35 (16.3) 
Stiffness subscale  41 (18.7) 45 (20.9) 
Function subscale  34 (16.5) 35 (17.6) 
Total score  34 (14.6) 36 (16.8) 
SF-36 measures   
Physical component summary 36.5 (9.1) 37.0 (8.5) 
Mental component summary 53.7 (11.2) 52.7 (11.0) 
Human Activity Profile score   
Maximum activity  77 (8.2) 73 (9.6) 
Adjusted activity  63 (12.4) 61 (13.7) 
Accelerometer score   
Number of days of use  6 (0.3) 6 (0.4) 
Daily accelerometer counts  178,181 (82,192) 211,250 (98,574) 
Daily resting time in minutes 992 (90.5) 972 (94.8) 
Daily light activity in minutes 333 (78.6) 345 (78.3) 
Daily moderate activity in minutes 105 (56.8) 122 (63.6) 
Daily hard activity in minutes 0.1 (0.3) 0.2 (0.6) 
 
 
p=0.04; † control (n = 31), PES (n = 33); ‡ control (n = 35), PES (n = 29); Abbreviations: 
PES - pulsed electrical stimulation; SD – standard deviation; BMI – body mass index; VAS 
– visual analogue scale; WOMAC – Western Ontario and McMaster Universities 
Osteoarthritis Index; SF-36 – Medical Outcomes Study 36-item Short-Form Survey version 
2. 
 
Participants used a variety of non-steroidal anti-inflammatory and analgesic 
medications, as well as combinations of fish oil and glucosamine. At baseline, while 
there was a trend to less analgesic use in the PES group, there were no statistical 
differences between the groups in use of either prescribed or complementary 
medication (Table 1). Over the 26 weeks, there was little variation noted in either the 
type of medication used or the dosage in either group. Six participants failed to 
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complete their medication diary while seven who did complete their diary were not 
using any medication for OA. 
Device use, adverse effects and blinding  
At 26 weeks, 20 (59%) of the PES group and 13 (36%) of the controls achieved 
100% or greater target usage (p=0.03). However, effective device use defined as 
achieving 80% of the prescribed target did not differ significantly between groups 
(PES 25 (74%), control 22 (61%), p=0.11). The decision to define 80% of the 
prescribed target as effective device use closely reflected the minimum end of the 
accepted device use range of six hours per day reported in previous studies (5, 6, 8). 
Twelve participants had adverse skin reactions in the form of rashes that were 
localized and mild. There was no difference between groups in the proportion of 
participants affected (6 (18%) PES, 6 (17%) control, chi sq = 0.1; p=0.9). Affected 
participants were advised to desist from device use until the rash had settled, after 
which they were able to resume treatment. Two participants from the control group 
used the device intermittently because of recurring skin reactions. 
Thirty-one participants believed they knew whether their device was active or not but 
their ability to identify their group correctly did not differ from chance (6 (50%) 
PES, 10 (53%) control, Kappa = 0.02, p = 0.9). Thirty-five participants (19 PES, 16 
control) did not know whether their device was active or inactive and four others did 
not complete the question. Thirteen of the 15 participants who believed they had 
used the active device reported feeling better on the GPES. Conversely, of the 16 
who believed theirs was inactive, 13 reported no change or worse on the GPES 
(Kappa = 0.68, p<0.001). This suggests that blinding of participants was successfully 
maintained as participants’ opinion on which device they had been allocated was 
largely influenced by their outcome.  




Pain and function 
For pain, PGA and function, there were statistically significant within subject 
changes in each group over 26 weeks except for WOMAC pain and function in the 
PES participants. However, between group mean differences in change for pain VAS 
0.9, (CI -11.7 to 13.4); WOMAC pain -5.6, (CI-14.9 to 3.6), PGA -2.8, (CI -13.8 to 
8.4) and; function -1.9, (CI -9.7 to 5.9) were not significant (Table 2). Interestingly, 
mean change in pain VAS over 26 weeks approached MCII, unlike PGA or function 
scores (Table 2). There were no between group differences for changes in pain, PGA 
or function at any of the earlier time points (Figure 2). 
The proportion of participants achieving MCII for pain VAS at 26 weeks did not 
differ significantly between groups (19 (56%) versus 16 (44%) for PES and control 
respectively; 95% CI -11% to 33%; p=0.47) (Table 3).  
Quality of life and activity 
The SF-36 physical component summary measures (PCS) were slightly below and 
the mental component summary measures (MCS) slightly above the OA population 
norm (Table 1) (30). Only small improvements in PCS and MCS occurred over 26 
weeks with no statistical differences between groups (Table 2). Patterns of change 
observed in the subscale scores were similar to those in the summary scores (Table 
4). 
Changes in both HAP and accelerometer physical activity measures at follow-up 
were small with no significant differences between groups (Table 2). 
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Table 2 Changes from baseline in outcome variables . Data represent change at 26 
weeks unless otherwise indicated. 











Pain VAS (mm) 18.7 (31.1) 19.6 (20.7) 0.9 (-11.7 to 13.4) 0.89 
Patient global assessment  
VAS (mm) 14.1 (28.0) 11.3 (17.9) -2.8 (-13.9 to 8.4) 0.62 
WOMAC (all normalized/100)     
Pain subscale 10.1 (18.4) 4.5 (20.4) -5.6 (-14.9 to 3.6) 0.23 
Stiffness subscale 4.7 (19.3) 8.5 (21.5) 3.7 (-6.0 to 13.5) 0.45 
Function subscale 6.9 (16.2) 4.9 (16.5) -1.9 (-9.7 to 5.9) 0.62 
Total score 6.8 (15.5) 5.5 (16.0) -1.3 (-8.8 to 6.3) 0.74 
Medical Outcomes Study SF-36     
Physical component score -2.6 (7.3) -1.0 (5.6) 1.7 (-1.5 to 4.8) 0.30 
Mental component score -2.4 (8.1) -1.2 (9.3) 1.2 (-2.9 to 5.4) 0.55 
Human Activity Profile†      
Maximum activity score 1.1 (7.9) -1.0 (6.8) -2.0 (-5.6 to 1.5) 0.26 
Adjusted activity score 0.5 (8.8) 0.2 (6.2) -0.3 (-4.0 to 3.3) 0.86 
Accelerometer† (n=34) (n=33)   
Accelerometer counts –  
daily average 
-5,419 (52,488) 12,600 (52,409) 18,020 
(-7,566 to 43,607) 
0.16 
Daily resting time in minutes -11.8 (88.7) -27.6 (85.5) -15.8 (-58.3 to 26.7) 0.46 
Daily light activity in minutes 18.8 (67.6) 16.5 (65.2) -2.3 (-34.7 to 30.1) 0.89 
Daily mod activity in minutes -0.4 (36.3) 11.1 (41.2) 11.5 (-7.4 to 30.4) 0.23 
Daily hard activity in minutes -0.2 (1.0) -0.01 (0.7) 0.1 (-0.3 to 0.6) 0.51 
*Negative mean change values for SF-36, HAP, accelerometer counts, calories, moderate and hard activity 
all represent improvement. For all other variables, a positive change values represents improvement. 
†Physical activity measurement changes from baseline to 16 weeks. Abbreviations: PES – pulsed electrical 
stimulation; SD- standard deviation; CI – confidence interval; VAS – visual analogue scale; WOMAC – 
Western Ontario and  McMaster Universities Osteoarthritis Index; SF-36 – Medical Outcomes Study 36-
item Short-Form Survey version 2; mod - moderate. 
 
Global perceived effect scale 
Similar to most other indices, GPES scores at both 16 and 26 weeks did not differ 
between groups (16 weeks mean difference 0.11, 95% CI -0.83 to 1.04; 26 weeks 
0.78, -0.22 to 1.78).  
Adjustment for covariates including sample characteristics, baseline measures and 
amount of device use did not alter any of the findings for any of the variables. 




Table 3.   Results from secondary analysis. Number (percent) of participants 
achieving 20mm change in pain VAS and minimal clinically important improvements 
(MCII)* in PGA and WOMAC function at 26 weeks 







Pain VAS  16 (44) 19 (56) -11% to 33% 0.47 
PGA  16 (44) 13 (38) -28% to 16% 0.78 
WOMAC function  14 (39) 13 (38) -22% to 22% 1.00 
*MCII for PGA = 18.3; WOMAC function = 9.1 (17) Abbreviations: VAS – visual analogue scale; 
PGA – patient global assessment; WOMAC – Western Ontario and McMaster Universities 
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Figure 2  Scores for pain VAS, patient global assessment and function at each time 
point.   
Error bars indicate 95% CI.  There were no between group differences in change over time for any of these 
variables. 
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Table 4  Mean normalized values of Medical Outcomes Study Short-Form 36 survey 









Control  PES 
Base 4/52  16/52  26/52  
 
Base 4/52 16/52 26/52 
PF 38.97(12.75) 33.71 33.12 36.34 36.34  34.07 34.07 36.05 34.94 
RP 41.20(11.96) 39.17 39.71 40.46 41.48  39.78 41.41 41.37 41.66 
BP 40.77(09.86) 40.07 42.07 42.27 45.86  40.74 43.28 42.59 44.92 
GH 42.99(10.70) 49.44 48.52 50.70 49.43  46.91 46.30 46.63 44.89 
V 45.31(10.07) 48.28 48.19 50.70 50.62  48.51 49.34 49.70 48.79 
SF 43.69(12.54) 46.85 47.61 49.73 49.43  48.19 48.67 47.87 48.35 
RE 45.57(12.72) 45.41 48.00 48.43 49.62  45.03 46.51 45.26 46.62 
MH 47.56(10.64) 51.73 51.65 52.82 53.37  49.59 50.75 52.24 51.99 
PCS 38.85(11.81) 36.47 36.33 38.28 39.12  36.96 37.70 38.28 37.95 
MCS 48.72(10.98) 53.65 54.81 55.84 56.07  52.68 53.76 53.43 53.85 
Ware and Kosinski (21)  Abbreviations:SF-36 Medical Outcomes Study Short-Form 36 Survey; OA - 
osteoarthritis; PES - pulsed electrical stimulation; Base – baseline; PF – physical function; RP – roles 
physical; BP – bodily pain; GH – general health; V – vitality; SF – social functioning; RE – roles 




In patients with OA of the knee, PES treatment over 26 weeks was no better than 
placebo for reducing pain and improving physical function. Our results were 
consistent across all time points and outcome measures. Importantly, individual 
outcome results were reflected by the participants’ overall perception of their 
response to treatment in the GPES. An unacceptably low proportion of participants 
using PES achieved the MCII for pain, PGA and function. Moreover, the control 
group responses were comparable. 
 




Comparison with other studies 
Previous randomized controlled trials of PES, conducted under the auspices of 
Bionicare®, the commercially available equipment, have reported favourable 
responses to PES compared with placebo (6, 8). Our results are clearly different.  
Both our PES and placebo electrical parameters and method of application were 
comparable to Bionicare® in frequency (100Hz) and wave form (spiked, 
exponentially decreasing shape). Zizic et al (8) and Garland et al (6) described their 
current as monophasic but ours was slightly biphasic to avoid skin irritation (31). 
Comparison of our 16 week mean change data with the 12 week data reported by 
Garland et al (6) reveals strikingly similar ‘PES treatment group’ outcomes. The 
mean change for pain VAS in our study was 12.0 (22.6) mm whilst that reported by 
Garland et al was 14.7 (23.1) mm. However, while our placebo device response is 
consistent with that expected in osteoarthritis clinical trials (32) with a mean change 
of 14.4mm (SD 27.44), the placebo group in Garland et al changed very little with a 
mean change of 2.3mm (SD 21.95). This comparison was consistent across the three 
primary efficacy variables of pain, PGA and function and indicates that the 
difference in study outcomes appears to be due to differences in placebo responses, 
rather than differences in PES characteristics or equipment. 
The possibility that the three minutes of placebo treatment could be therapeutic 
should be considered. However, as the placebo device used by Zizic et al (8) and 
Garland et al (6) also delivered three minutes of treatment and did not show a 
therapeutic effect, this is unlikely to be the case. 
A comparison between the sample characteristics reported by Garland et al (6), Zizic 
et al (8) and amongst the participants in our study is limited by the different outcome 
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measures used and characteristics reported. However, in both the Garland et al (6) 
and Zizic et al (8) studies, higher scores in function at baseline were recorded 
meaning that OA was impacting on the health status of their participants to a greater 
extent than it was on participants in our study. Additionally, while the pain VAS 
scores reported by Garland et al (6) were similar to ours, their WOMAC pain scores 
were higher. Where reported, age and years since diagnosis were similar, while 
Garland et al’s (6) participants had higher BMI scores and a higher proportion of 
females (66% versus 47% respectively). It is unlikely that these differences account 
for the contrasting results. 
Placebo effect 
A therapeutic response to placebo treatment is well documented in the OA literature 
(32, 33). A number of characteristics of our study have previously been noted to 
contribute to a robust placebo response (32, 34-36).  Blinding was apparent 
throughout and the level of commitment required to participate was considerable and 
over an extended period of time. Furthermore, pain was the primary outcome. 
Participants had also been informed that previous trials of the modality had produced 
encouraging results so their expectations concerning improvement, along with their 
desire to contribute in an affirmative way, may have contributed to the positive 
response to the placebo control device.  
Sample characteristics 
Men accounted for just over 50% of the sample, whereas OA of the knee is usually 
more prevalent in women in the age group represented by this sample (37, 38). The 
mild to moderate baseline pain scores, mild levels of disability and high physical 
activity levels are also not typical. Thus the sample may not be representative of the 
OA population.  




It may be that PES is more effective in some subgroups of people with OA. It is well 
recognised that OA is a heterogeneous disease (39-41) and that causes of pain and 
pain mechanisms in OA are multi-factorial (42-44). PES may be a more appropriate 
treatment modality in those patients in whom local pain mediators, which rely on 
membrane ion channels that may be affected by externally applied electrical 
stimulation, are the main cause of pain. In contrast, those in whom biomechanical 
changes or psychosocial factors are the main contributors to pain production may be 
less responsive. These latter factors were not measured in this study. 
Therefore, while the outcome of this study is decisive, it may not be possible to 
generalize the results to the wider OA population.  
Physical activity 
Both accelerometer and HAP scores confirmed moderate levels of activity of the 
cohort at baseline. This may have limited the scope for further improvement and 
suggests that study participants were managing the functional impact of their disease 
quite well. However, as accelerometer data were recorded and reported cumulatively, 
determining whether moderate physical activity was performed in blocks of at least 
10 minutes as recommended by Haskell et al  (29) for general health improvement 
was not possible. 
Strengths and limitations 
The study was designed so that reporting of results conforms to the CONSORT 
statement (45). Both the sub-sensory nature of PES and robust allocation 
concealment meant blinding was a major strength of this study. All participants were 
screened, assessed and managed over 26 weeks by one experienced musculo-skeletal 
physical therapist thus avoiding investigator bias.  
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The recruitment of highly motivated volunteers may have resulted in a sample with 
characteristics different from the OA population in general. Additionally, the strong 
sense of commitment and desire to please noted in these participants may have 
enhanced the placebo response. It is unknown what influence these sample 
characteristics have had on the overall study outcome. 
A priori calculation of sample size based on the achievement of a 20mm 
improvement in the PES group over that achieved by the placebo group had the 
potential to limit results interpretation given that a minimum baseline pain VAS 
score of 25mm was an inclusion criterion for the study. That is, if a substantial 
number of PES group participants were to achieve a final pain VAS score of zero 
mm and a similar number in the placebo group were to achieve pain VAS scores less 
than 20mm, the capacity to detect a 20mm difference between the two groups would 
have been compromised.  However, as only one person in the whole sample (a PES 
group participant) achieved a pain VAS score of zero mm at 26 weeks, a true 
difference between the groups was able to be calculated and reported. 
So as not to disadvantage those in the control group over such a lengthy period, 
participants were instructed to continue with their usual OA management. Apart 
from medication no concurrent treatments were recorded. Consequently there may 
have been unknown confounding factors that may have influenced the outcome. 
CONCLUSION 
In this sample with mild to moderate symptoms and moderate to severe X-ray 
evidence of osteoarthritis of the knee, PES was no more effective than placebo in 
achieving improvements in pain, function, quality of life or physical activity. Results 
of this study therefore do not support more widespread use of this modality. 
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Chapter 7: Summary and main findings 
7.1  Introduction 
Osteaorthritis of the knee is a chronic disease contributing considerably to worldwide 
health burden (Felson et al. 2000; Walker-Bone et al. 2000; Symmons et al. 2003; 
Woolf and Pfleger 2003; Buckwalter et al. 2004; 2006; Sharma et al. 2006).  
Currently the only treatments readily available target symptoms (Altman et al. 2000; 
Jordan et al. 2003; Sarzi-Puttini et al. 2005) and have moderate effect sizes at best 
(Jordan et al. 2003). Further, available treatments are often limited in their use 
because of side effects or because co-morbidities restrict their use (Gislason et al. 
2006; Solomon et al. 2006). 
Physiotherapists use a variety of modalities to treat people with OA including, but 
not limited to, exercise prescription, muscle strengthening programs, manual therapy, 
and electrotherapy modalities. One such electrotherapy modality, PES delivered at 
sub-sensory intensities, has previously been reported to be effective in managing the 
symptoms of OAK (Zizic et al. 1995; Farr et al. 2006; Mont et al. 2006; Garland et 
al. 2007; Fary et al. 2009). All previous studies were conducted  with varying 
degrees of support from the company that produced the equipment, and both RCTs 
(Zizic et al. 1995; Garland et al. 2007) were of only short duration (four and 12 
weeks respectively).  
PES is relatively inexpensive, non-invasive, non-pharmaceutical and has few side 
effects. Consequently, independent verification of its effectiveness was warranted in 
order to determine if it was a viable treatment option for OAK. The aim of this thesis 
was therefore to explore, independent of device manufacturers, the effectiveness of 
PES in treating symptoms of OAK over 26 weeks.  This chapter provides a summary 
of the steps required and the research undertaken to achieve this aim.  It discusses the 
findings, outlining strengths and weakness, of each step. Finally, the overall 
implications of this research are discussed.   
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7.2  Pilot study of pulsed electrical stimulation   
Prior to commencement of this part of this initial doctoral research project there was 
only one published report on PES. This was a randomised, placebo controlled trial 
conducted over a period of four weeks (Zizic et al. 1995). Outcome measures in that 
study included: pain, patient assessment of function, and physician global 
assessment, all measured on a 10cm VAS; patient assessment of duration of morning 
stiffness in the knee (minutes); knee range of motion (goniometer); joint tenderness 
on palpation and swelling (both 4-point Likert); knee circumference (inches); and 50 
foot walking time (seconds). Improvements in pain, function, physician global 
assessment, and joint morning stiffness duration were reported. 
Only two of the three primary efficacy variables of pain, function and PGA now 
recommended for use in clinical trials of OA were included (Bellamy et al. 1997; 
Hulme et al. 2002) with PGA not being used. In addition, only the VAS used to 
assess pain would currently be considered a measurement tool of choice. 
The pilot study of this thesis (Fary et al. 2009) was undertaken to develop familiarity 
with use of the BioniCare  BIO-1000TM PES equipment, assist with the 
development of the protocol for the E-PES trial, provide experience with subject 
recruitment and retention, and develop an understanding of compliance with use of 
equipment and any adverse effects that may arise. In doing so it provided the 
opportunity to evaluate the effectiveness of PES over 16 weeks using a greater 
variety of outcome measures. All three recommended primary efficacy variables 
were included (pain VAS, function using OAK specific questions and PGA VAS). 
Additionally, QoL (SF-36), physical activity (accelerometer) and GPES (11-point 
Likert) were measured.  
The equipment was well tolerated with adherence being 63%, 83% and 102% of 
target dosage and there were no adverse skin reactions. This was promising given 
that the proposed E-PES trial was to continue for 26 weeks duration. There was a 
trend towards improvement in the measures of pain, function, PGA and ambulation 
with this trend being reflected in two of the three patients who recorded an overall 
improvement in the global perceived effect scale. The third reported no change on 
the global perceived effect scale.   
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Limitations of this study included: 
 the very small number of patients reported; and 
 the use of  accelerometers alone, while being valid and reliable measurements of 
ambulatory activity, did not measure other activities beneficial to health such as 
cycling and swimming. 
The case studies provided valuable experience with the research process and the 
expanded range of outcome measures. While having its limitations, the largely 
positive response to PES was consistent with previous reports (Zizic et al. 1995; Farr 
et al. 2006; Mont et al. 2006; Garland et al. 2007) and suggested that the modality 
may be an effective treatment option over 16 weeks for people with OAK. This 
provided further support for conducting a RCT of longer duration.  
7.3  Development of pulsed electrical stimulation equipment  
As the BioniCare  BIO-1000TM devices were not available for the proposed E-PES 
trial, it was necessary to develop appropriate equipment for the study to continue. 
The major consequence of this was that the E-PES trial would be the first fully 
independent investigation into PES to be conducted. 
Metron Digi-10s TENS units were sourced and modified to exactly replicate the 
parameters reported in the PES literature (Zizic et al. 1995; Farr et al. 2006; Mont et 
al. 2006; Garland et al. 2007). These parameters were described as a pulsed, 100 Hz 
frequency, monophasic current with a spiked, exponentially decreasing wave form. It 
has to be said that it is unusual for monophasic current to be used in this manner 
because a common side effect of its use is skin irritation and chemical burns (Hooker 
2001). Being pulsed monophasic rather than continuous monophasic partially 
alleviated concerns about this current type. This is because pulsing allows the skin to 
act as a capacitor and discharge current thereby limiting chemical build up under the 
electrodes (Robertson et al. 2006). Nevertheless, it was not entirely surprising when 
initial testing of our pulsed monophasic prototype produced unacceptable adverse 
skin reactions with short durations of use.  
These initial responses to the monophasic prototype led to the development and 
comparative testing of a biphasic PES device. The other current parameters of 
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pulsed, 100 Hz frequency and spiked, exponentially decreasing wave form remained 
the same. Biphasic current was chosen as it is even less likely than pulsed current to 
produce adverse skin reactions. This is because the changing direction of current 
flow means there is little opportunity for chemical build up to occur under the 
electrodes. 
Comparative testing of the monophasic and biphasic prototypes was conducted and 
reported in chapter 4. 
Another critical element of the E-PES trial was the placebo device. The placebo used 
by Zizic et al. (1995) and Garland et al. (2007) delivered three minutes of PES prior 
to ceasing current flow. Consequently, a placebo device that delivered three minutes 
of biphasic PES prior to ceasing current flow was constructed. As the current was 
delivered at a sub-sensory intensity and the LCD screen on the device did not alter, 
the cessation of electrical stimulation went unnoticed. Importantly, there was no way 
of recommencing current flow in this placebo unless the on-off switch was turned off 
and the procedure for re-setting the intensity was undertaken. This feature meant that 
it would be unusual for participants in the placebo group to get more than three 
minutes of the active PES treatment each day. 
The method of application of PES described in the literature (Zizic et al. 1995; Farr 
et al. 2006; Mont et al. 2006; Garland et al. 2007) was also replicated. Neoprene 
wraps using a three point Velcro securing system were made to encase the 
electrodes. Electrode placement was the same with the anode on the distal third of 
the anterior thigh and the cathode positioned anterior to the knee joint while anti-
allergenic coupling gel was used on electrode pockets constructed to match the size 
of the electrodes used with the BioniCare  BIO-1000TM. 
At the end of the equipment development phase all aspects, except for the 
substitution of biphasic for monophasic current, of application of the modality had 
been faithfully replicated and a robust placebo device constructed. 
7.4  Prototype equipment testing study  
Twenty-five healthy subjects were recruited to test the rate of adverse skin reactions 
using both the monophasic and biphasic current device prototypes. This study (Fary 
and Briffa 2010) confirmed that the monophasic device produced unacceptable rates 
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of adverse skin reactions (52%) in healthy subjects and that these rates differed 
significantly from those reported in three of the four previously published PES 
studies (Zizic et al. 1995; Farr et al. 2006; Garland et al. 2007). Only Mont et al 
(2006) reported a similar adverse skin reaction rate (45%).  By contrast, the slightly 
biphasic prototype was well tolerated and produced an adverse skin reaction in one 
subject. 
This study supported the caution generally advised in the electrotherapy literature 
regarding the use of monophasic current while contradicting the assertions made by 
the authors of previous PES papers (Zizic et al. 1995; Farr et al. 2006; Mont et al. 
2006; Garland et al. 2007) that conduction gel was the main cause of the adverse skin 
reactions reported. 
There were key differences in the application of PES in the prior literature when 
compared to the monophasic PES prototype testing (Fary and Briffa 2010). All 
previous clinical trials had reported PES use for lengthy durations and had used gel 
as the coupling agent. The prototype testing limited use to a maximum of 15 minutes 
and water was used as the coupling agent. If either gel or duration of use were a 
major cause of adverse skin reaction, the rate of adverse skin reactions in the 
monophasic prototype testing should have been less than the previously reported 
rates. 
Whether there were particular electrical parameter characteristics not articulated, or 
not identifiable, in the previous PES publications is unknown. What is known is that 
exact replication of the reported current characteristics, by a senior biomedical 
engineer with considerable experience in this area, produced unacceptable rates of 
adverse skin reactions.  
Limitations of this study included: 
 A change in protocol from 15 minutes testing to 10 minutes testing during 
implementation of the study as a result of three of the first five subjects sustaining 
an adverse skin reaction after use of monophasic PES. This change was accepted 
on the basis that a shorter testing duration was long enough to test the hypothesis 
and would be safer for the participants in the study. 
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 The absence of investigator blinding to the type of device used on each knee and 
the same investigator reporting on adverse skin reaction rates. However, where 
adverse skin reactions were evident, independent confirmation was provided by 
participants being required to report on duration of the response 24 hours after the 
testing.  
 The inability of five participants to achieve a sub-sensory state with the 
monophasic prototype. These results were included in absolute rates of adverse 
skin reaction reports but were excluded from comparison with published literature 
because all published literature reported use of PES at a sub-sensory level. 
The results derived from this comparative testing of the monophasic and biphasic 
PES prototypes provided justification for using a biphasic current in the E-PES trial 
rather than a pure monophasic one.  
7.5  Effectiveness of pulsed electrical stimulation trial research 
protocol  
Despite the limitations of the PES literature discussed in chapters 1 and 3, the 
consistently positive results reported by Farr et al. (2006), Fary et al. (2009), Garland 
et al. (2007), Mont et al. (2006) and Zizic et al. (1995) and the putative capacity of 
PES to act as a disease modifier (Lippiello et al. 1990; Wang et al. 2004; Brighton et 
al. 2006; Brighton et al. 2008) provided strong support for further research. 
A double blind, randomised, placebo-controlled, repeated measures trial design was 
chosen as it provided the best opportunity to objectively assess the effectiveness of 
PES. Key methodological elements described by Herbert (2000) were included in the 
protocol. Computer-generated block randomisation combined with stratification was 
conducted by a person independent of the trial. A successful randomisation process 
and allocation concealment ensured that potential bias within the trial was reduced 
(Beller et al. 2002; Nuesch et al. 2009). Because all devices looked the same, and 
were applied and used in the same manner, blinding of both the investigators and the 
participants to device allocation was maintained until after data were analysed.  
Outcome measures that were all valid and reliable for the target sample were chosen 
(Sanson-Fisher and Perkins 1998; Brazier et al. 1999; Melzack and Katz 1999; 
Ehrich et al. 2000; Ware et al. 2002; Welk 2002; Bellamy 2004; Bennell et al. 2004; 
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Pengel et al. 2004; Ward et al. 2005) while the three primary efficacy variables (pain, 
function and PGA) recommended for use in arthritis trials by the OMERACT group 
were included. Physical activity was measured in addition to function because of its 
important contribution to health and well-being (Haskell et al. 2007). Two measures 
were used to determine this outcome because of the known difficulties with 
measurement precision.  The HAP is a valid and reliable self-report questionnaire 
(Fix and Daughton 1988). However, it is subject to the limitations associated with 
self-report activity measurements including recall bias (Ainsworth and Coleman 
2006). Consequently, accelerometers that provide a direct measure of ambulatory 
physical activity were used to complement the HAP.  
As OA is a chronic disease, treatment needs to be effective in the long term. A period 
of 26 weeks was chosen to reflect disease chronicity and was 14 weeks longer than 
the longest previous RCT published during the development of the research for this 
thesis (Garland et al. 2007). In addition, this period of time allowed for assessment of 
the ease of, and compliance with, use of the device. These latter aspects were 
considered to be important if, in the event of effectiveness being demonstrated, 
further research into effects on cartilage were to be undertaken. 
The interim data collection time points of four and 16 weeks were chosen to allow 
comparison with previous publications while also considering burden on participants. 
The four week time point reflected the end point in the 1995 trial by Zizic et al.  Four 
and 16 week data collection points were used in the pilot study undertaken for this 
thesis (Fary et al. 2009). The pilot study provided research experience with the time 
frames and indicated that participants would manage the time distribution well.  
The RCT by Garland et al. (2007) extended to 12 weeks. A direct 12 week 
comparison with our trial would clearly have provided additional information. 
However, the E-PES trial data collection time points were set a priori, the protocol 
planned and research funding grants acquired prior to Garland et al.’s (2007) 
publication. To add another data collection point would have increased the burden on 
trial participants and was considered unwarranted.  
It was determined that only one investigator, an experienced musculo-skeletal 
physiotherapist, would have contact with participants for the duration of the trial. 
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This was to eliminate any bias that may have been introduced by different clinical 
and/or communication approaches with participants.  
Finally, the manner of application (neoprene wraps and size and placement of 
electrodes) was chosen to replicate the previous studies. 
7.6  Results of the E-PES trial   
Results of the E-PES trial showed that, in the sample studied, PES over 26 weeks 
was no better than placebo in improving pain, function, PGA, QoL and physical 
activity (Chapter 6). These results were clearly different to the previous RCTs of 
shorter duration (Zizic et al. 1995; Garland et al. 2007). 
7.6.1   Comparison with other trials  
The sample characteristics reported by Garland et al. (2007) and Zizic et al. (1995) 
were compared with those in our trial. While the comparison is limited by the 
different outcome measures used and characteristics reported, both Garland et al. 
(2007) and Zizic et al. (1995) reported higher scores in function at baseline meaning 
that OAK was impacting on the health status of their participants to a greater extent 
than it was on participants in our trial. Additionally, while the pain VAS scores 
reported by Garland et al. (2007) were similar to ours, the WOMAC pain scores were 
higher. As WOMAC pain scores are related to functional tasks, this is consistent with 
OAK having a greater impact on their participants than on ours.  
It was not possible to compare the radiographic scores in Zizic et al. (1995) with 
those in the E-PES trial because a different measurement (Lequesne’s) was used and 
baseline data were not presented. However, all participants in the Garland et al. 
(2007) trial had Kellgren-Lawrence radiographic scores of 3 or 4, signifying 
moderate to severe radiographic disease, whereas 69% of the participants in the E-
PES trial had these scores. Where reported, age and years since diagnosis were 
similar, while Garland et al.’s (2007) participants had higher BMI scores and a 
higher proportion of females (66%) than we did (47%). It is unlikely though that 
these differences alone account for such contrasting results. 
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Table 7.1  Pain VAS comparisons between E-PES trial and Garland et al. (2007) 
 Pain VAS 
 Baseline  Follow up † Change  
Treatment devices    
E-PES trial 51.5 (17.2) 39.5 (23.6) 12.0 (22.6) 
Garland et al 50.9 (17.9) 36.2 (26.1) 14.7 (23.1) 
Placebo devices    
E-PES trial 52.3 (18.2) 37.8 (23.8) 14.4 (27.4) 
Garland et al 48.1 (16.8) 45.7 (21.8) 2.3 (22.0) 
 Mean (SD); † E-PES follow up 16/52, Garland et al. (2007) follow up 12/52 
Abbreviations: VAS – visual analogue scale, E-PES – effectiveness of pulsed electrical stimulation. 
 
 
All other PES studies have used the Bionicare® BIO-1000™ device. Of concern for 
this thesis was that the results of the E-PES trial might have been different to 
previous ones purely because of the slightly different current parameters used. In 
order to address this concern, comparisons were made between the E-PES trial 16 
weeks mean change data and those reported at 12 weeks by Garland et al. (2007).  
Strikingly similar ‘PES treatment group’ outcomes are apparent in the pain VAS 
scores in the two studies (Table 7.1). However, while our placebo device response 
was consistent with that expected in OA clinical trials (Zhang et al. 2008) it was very 
different to those reported by Garland et al. (2007) (Table 7.1).  
There was variability in the results for PGA and function between the studies (Table 
7.2). Baseline data for both PGA and function confirm the greater impact that OAK 
was having on participants in the Garland et al (2007) trial in comparison to ours. 
The larger mean changes noted in both these variables in the treatment group from 
Garland et al. (2007) may reflect the greater scope for improvement these 
participants had available. Of note, function in Garland et al.’s (2007) treatment 
group was, in fact, the only outcome variable to achieve a mean change greater than 
or equal to its MCII benchmark of 9.4 (Tubach et al. 2005).  
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Table 7.2  Patient global assessment and function comparisons between E-PES 
trial and Garland et al (2007)  
 Patient Global Assessment  Function 
 Baseline  Follow up † Change   Baseline  Follow up † Change  
Treatment 
devices 
       
E-PES 44.3(19.3) 36.8(21.2) 7.5(16.5)  35.2(17.6) 31.2(18.7) 3.9(13.8) 
Garland  51.3(17.4) 39.3(26.1) 12.9(24.5)  51.9(16.0) 39.9(24.6) 12.0(19.2) 
Placebo 
devices        
E-PES 46.6(24.4) 42.1(19.8) 4.4(26.2)  33.7(16.5) 24.6(15.6) 9.1(14.7) 
Garland  41.4 (16.1) 45.1(21.4) -3.7(23.43)  44.9(14.9) 46.6(18.3) -1.7(13.5) 
* Mean(SD); †E-PES follow up 16/52, Garland et al. (2007) follow up 12/52. Abbreviation: E-PES – 
effectiveness of pulsed electrical stimulation 
 
By contrast, the PGA and function responses in the placebo group in Garland et al.’s 
trial (2007) were minimal. In fact, a slight mean change for the worse in both PGA 
and function variables was demonstrated (Table 7.2). This differs markedly from the 
responses demonstrated by those using the placebo devices in the E-PES trial. 
Positive mean changes for both PGA and function were achieved, with that for 
function approaching the MCII for that variable. Again our placebo responses are 
consistent with that expected in OA clinical trials (Zhang et al. 2008). 
The concerns that BioniCare Medical Technologies Inc had verbally expressed about 
their placebo device are also important to note. Participants using it could turn up the 
intensity and receive a further three minutes of treatment. That is, the current flow 
cut out after three minutes but would automatically come back on if the intensity was 
readjusted. The placebo device developed for our trial did not allow this to happen. 
Consequently, if there were to be a difference between studies in placebo responses, 
it might have been expected that the Bionicare® response would have been the larger 
one given the potential for increased dosage of PES. 
It appears that the differences between results reported in the E-PES trial and those in 
Garland et al (2007) are more likely due to differences in placebo responses and not 
due to differences in PES characteristics or equipment. 
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7.6.2   Placebo   
Placebo responses in OA studies are sizeable (Zhang et al. 2008). Factors such as 
maintenance of blinding and treatment aims that include a reduction in pain 
contribute to a robust placebo response (Zhang et al. 2008). Additionally, it has been 
noted that placebo responses tend to increase in trials of longer duration (Walsh et al. 
2002), in trials where there are larger active treatment effect sizes (Zhang et al. 2008) 
and where patients consider the intervention to be a new treatment (Doherty and 
Dieppe 2009). Further, placebo responses are also strongly affected by expectations 
of treatment effectiveness, desire for improvement in symptoms and the treatment 
environment (Koshi and Short 2007; Linde et al. 2007; Benedetti 2008; Price et al. 
2008; Finniss et al. 2010).  
The E-PES trial design had characteristics that could have demonstrably contributed 
to a large placebo effect. Blinding was apparent throughout, pain was the primary 
outcome, and the level of commitment required to participate was considerable and 
over an extended period of time. As the treatment is not in widespread use it was also 
perceived as being a new and modern intervention by the participants. 
Participants were all volunteers and had been informed that previous trials of the 
modality had produced encouraging results. As a consequence, their expectations 
regarding improvement, the supportive environment of a clinical trial, and their 
willingness to contribute all may have contributed to the placebo group responses.  
The possibility that the three minutes of placebo treatment per day could be 
therapeutic should be considered. However, as the placebo device used by Zizic et al 
(1995) and Garland et al (2007) also delivered three minutes of treatment and did not 
show a therapeutic effect, this is unlikely to be the case. Additionally, reported 
effective dosages used for related electrotherapeutic modalities such as TENS and 
interferential consistently exceed an average of three minutes per day (Adedoyin et 
al. 2002; Johnson 2008; Rutjes et al. 2009) 
7.6.3   Sample characteristics  
Men accounted for slightly greater than 50% of the sample whereas OA of the knee 
is more prevalent in women in the age group represented by this sample (van Saase 
et al. 1989; Felson 2006). The mild to moderate baseline pain scores, mild levels of 
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impairment and disability and higher than usual physical activity levels are also not 
typical suggesting the sample may not be representative of the wider OAK 
population.  
Additionally, the SF-36 MCS shows that participants in the E-PES trial demonstrated 
a general sense of well-being that would be expected in the normal population and 
that the subscale scores of general health, vitality and social functioning were also 
above those usually found in the OA population (Table 4 in chapter 6).  These results 
suggest a group of people with a positive outlook on life and good social support 
networks. These attributes are considered to have a mediating influence on a person’s 
pain perception (Ferreira and Sherman 2007) and confirm this self-selecting sample 
of volunteers appeared to be managing their OAK better than usual OAK study 
populations.  
It is unknown what influence these sample characteristics may have had on the trial 
outcome. However, they do suggest that some caution be exercised when 
generalising the trial results to a wider population of people with OAK.  
7.6.4   Physical activity  
The moderately active HAP scores in the E-PES trial are consistent with those 
described by Bennell et al. (2004) where people with OAK and people without OAK 
were able to be distinguished on the basis of their HAP AAS. Bennell et al. (2004) 
demonstrated that people with OAK, while still being classified as moderately active 
using the HAP, were less active than those without OAK (Bennell et al. 2004). That 
people with OA are generally less physically active than people without OA has also 
been reported in large epidemiological studies (Hootman et al. 2003; Shih et al. 
2006).  
The HAP questionnaire asks whether or not a person is currently still performing a 
task. A limitation of this tool is that frequency, duration and intensity of the task are 
not recorded. That is, a person may record that he or she is still bicycling for one 
kilometre. However, the frequency and intensity at which this task is completed is 
not measured. As a consequence, a person with OAK may be classified as 
moderately active using the HAP yet may not meet the recommended physical 
activity guidelines where intensity and duration are included (Haskell et al. 2007; 
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Brown et al. 2008). In the epidemiological studies (Houghton et al. 2003; Shih et al. 
2006), the type, frequency, intensity, and duration of specific activities were recorded 
by interview thus providing more detail about the activity. Additionally, it is 
recognised that the ability of the HAP to respond to interventions is yet to be 
determined (Bennell et al. 2004). 
Accelerometer data in the E-PES trial nevertheless reflected the HAP scores and 
demonstrated that this particular group of people with OAK were achieving more 
than the minimum of 30 minutes of moderate intensity activity recommended every 
day for the general adult population (Haskell et al. 2007). Accelerometer data also 
showed that this group were meeting the recommendations that people with OA of 
the hip and knee should accumulate 30 minutes of moderate intensity physical 
activity or exercise on at least three days per week (Minor et al. 2003). Once again 
though, limitations in the recording instrument are noted.  The accelerometer data 
were recorded and reported cumulatively and, without conducting more detailed 
manual data extraction, it was not possible to determine the pattern of activity. That 
is, whether moderate physical activity was performed in blocks of at least 10 minutes 
as recommended by Haskell et al (2007). Additionally, no record of the specific 
nature of the activity was recorded. For example, it is unknown how much 
strengthening, endurance, coordination/balance and functional exercise was being 
undertaken to enhance health status.  
While recognising limitations in the instruments used, that each measurement tool 
reflected the other is of note. Confirmation that both groups were, in general, at least 
moderately physically active at baseline reduced the likelihood of large increases of 
activity occurring. The very small changes detected in both HAP scores and 
accelerometer data over 16 weeks appeared to confirm this. Equally, the change in 
physical activity measures reflected those of all the other variables studied in the trial 
with no difference between the PES and placebo groups being noted. 
7.6.5   Strengths of the E-PES trial  
The trial was designed so that reporting of results would conform to the CONSORT 
statement (Begg et al. 1996; Moher et al. 2001). Consequently it included key 
elements such as clear participant eligibility criteria; a priori power and sample size 
calculations; pre-specified primary and secondary outcome measures; computer-
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generated randomisation and device allocation conducted by someone independent of 
the study; and intention to treat data analysis using confidence intervals. It was 
registered prior to commencement, funding sources were acknowledged and the full 
protocol was published.  Additionally, only valid and reliable outcome measures for 
the trial population were used.  
The sub-sensory nature of PES and robust allocation concealment meant that 
blinding was successfully maintained until after data analysis was complete. 
Additionally, all participants were screened, assessed and managed over the duration 
of the trial by the one experienced musculo-skeletal physiotherapist (RF). Any bias 
that may have resulted from different styles of clinical supervision and attention were 
thereby eliminated.  
Only two people formally withdrew (one from each group, before the 16 week data 
collection point) and another one person from the PES group failed to attend the final 
appointment at 26 weeks. The participant who withdrew from the PES group cited 
that using the device was uncomfortable while the other found the protocol too 
difficult for them. No reason for the failure to attend at 26 weeks was elicited. In the 
context of two very hot Western Australian summers during the time frame of the 
trial, maintaining 96% of the sample over 26 weeks was a very positive outcome. 
Finally, the trial was undertaken independent of industry funding thus avoiding any 
real or perceived bias in results.  
7.6.6   Limitations of the E-PES trial 
Since the participants were highly motivated volunteers, there may have been higher 
than usual levels of compliance with what was a protocol that required considerable 
commitment over a lengthy time period.  Additionally, highly motivated volunteers 
may have contributed to a sample with characteristics less representative of the OA 
population. Furthermore, their strong sense of commitment and desire to please may 
have enhanced the placebo response.  
So as not to disadvantage those in the control group over such a lengthy period, 
participants continued with their usual OA management. It was assumed that with a 
robust randomisation process any variations in usual management would be reflected 
in both groups. However, other than medications, no other treatments that were being 
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used at the outset or any new ones that participants may have added of their own 
volition over the 26 weeks were recorded. While PES would most likely be used in 
conjunction with other treatments in clinical practice, whether other treatments 
confounded the results or not is unknown. 
It is also well recognised that OA is a heterogeneous disease (Goldring and Goldring 
2007; Brandt et al. 2009; Felson 2009) and that causes of pain and pain mechanisms 
in OA are multi-factorial (Kidd 2006; Gwilym et al. 2008; Hunter 2008). This trial 
took a broad approach to disease diagnosis. It may well be that PES is an effective 
modality in those patients in whom local pain mediators are the main cause of pain 
where externally applied electrical stimulation may mediate the actions of 
inflammatory cytokines (Seegers et al. 2001). It also may be more effective in those 
for whom abnormal pain sensitivity is a feature (Bhave and Gereau 2004; Felson and 
Schaible 2009) where electrical stimulation may affect firing of the voltage-gated 
channels of the sensory nerve endings. However, systems to accurately identify these 
sub groups are yet to be established. Additionally, the trial was not powered to 
undertake any analysis of sub groups, in particular gender and baseline pain severity. 
Another potential limitation was the absence of another comparative group.  That is, 
a third arm with ‘usual treatment only’, or even a fourth where an intervention 
recommended in treatment guidelines like exercise or TENS was given. Given the 
size of the placebo effect in OA trials, a head to head randomised placebo-controlled 
trial in the absence of more sensitive selection criteria and larger sample sizes may 
be of limited value. There are though other limitations associated with the inclusion 
of these other arms. Blinding could not be maintained with either and the lack of 
outcome expectation within a ‘usual treatment only’ arm cannot be discounted in 
influencing the results. 
The intensity at which participants used their devices was not recorded. It is 
unknown whether there is a critical intensity at which sub-sensory treatment needs to 
be delivered to be effective. Additionally, device usage hours were recorded by 
participants on a self-report basis. 
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7.7  Implications of results and future directions 
This research provides evidence that PES is not an effective treatment option in 
managing symptoms associated with mild to moderate OAK over 26 weeks. It adds 
to the body of evidence regarding transcutaneous electrostimulation. A recent 
Cochrane review (Rutjes et al. 2009), which included the PES RCTs by Zizic et al. 
(1995) and Garland et al. (2007), proved to be inconclusive with regards the 
effectiveness of these types of electrotherapy modalities in providing pain relief for 
people with OAK. Small studies of questionable quality were cited as a reason for 
the inability to draw conclusions. It is contended that the E-PES trial, while still 
relatively small, was well-designed with adequate power to provide convincing 
evidence to contribute to any later meta-analysis of transcutaneous 
electrostimulation. 
Most importantly, this doctoral research provides information with low risk of bias 
regarding the effectiveness of this modality.  With the wide variety of treatment 
options available, people with OA and their health care professionals need to be able 
to make informed choices about best available treatment options. This research 
provides useful evidence on which these decisions can be made. 
The implications of continuing to use treatments that are not effective also need to be 
considered. Segal et al. (2004) presented data showing the cost-effectiveness of some 
commonly used treatments for OA and demonstrated that few of the most commonly 
used treatments had convincing evidence for cost-effectiveness. Currently, the 
commercially available PES device is being sold in the United States for $US1465 
(Calloway 2010). Our data would bring into question the cost-effectiveness of 
buying and using this device. In addition to the financial costs, continuing to use 
ineffective treatments does little to decrease the personal health burden for 
individuals with the disease. 
While the results presented here provide evidence against the use of PES for OAK, 
the limitations cited previously do suggest some direction for future research. 
Investigating the key characteristics of specific subgroups of OAK is of particular 
importance in that their identification may enable more appropriate targeting of 
treatment. Increased specificity in subject selection criteria may provide greater 
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opportunity to detect clinically meaningful differences when investigating the 
effectiveness of treatment modalities in managing OAK.  
The question regarding the putative disease-modifying effects of PES in vivo also 
remains unanswered. While this is a tantalising prospect to explore, until there is 
clear evidence of symptomatic improvement with long term use, it is difficult to see 
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Appendix 1a: Participant information form – pilot study   




















Appendix 1b: Participant information form – equipment testing 
study   







































Appendix 2a: Participant informed consent form – pilot study   






























Planning and administration checklist 






 letter of confirmation 
 parking permit 
 parking map 
 participant info sheet 
 
Visit 1 Final screening and subject details 
Informed consent 
Baseline data collection 
Accelerometer  
Confirm 2nd visit 
Parking permit 
Randomisation and 
allocation of device 
Visit 2 Return of accelerometer  
Teach use of PES 
Instruction booklet 
Medication diary and hours of use 
record 
Download 
accelerometer  data 
Enter data 
After 3/52 of use Send out 4/52 follow up 
questionnaires 
 letter with instructions 
 4/52 questionnaires 
 self-addressed, reply paid return 
envelope 
 
After 5/52 of use Ensure all 4/52 data collected and 
returned 
Enter data 
After 14/52 of use Phone contact re week 16 
appointment 
Send out: 
 letter of confirmation (ask them 
to bring in med diary) 
 parking permit 
 
Visit 3 
After 16/52 of use 
Complete questionnaires 
Distribute accelerometer  
Parking permit for return of devices 
Confirm date of return 
 
Visit 4 
After 17/52 of use 
Return of accelerometer  Download 
accelerometer  data 
Enter data 
After 24/52 Phone contact re week 26 
appointment 
Send out: 
 letter of confirmation 
 parking permit 
 
Visit 5 
After 26/52 of use 




Clean and check 
equipment 
Appendix 4: E-PES trial telephone screening form   














Pain and Patient Global Assessments 
 
 
Study Number _____ 
 
       Week Number ______
  
 
Visual Analogue Scale of Pain 
 
Consider the amount of pain that you have experienced due to arthritis 
in your treated KNEE over the past 48 hours. Please make a vertical 
mark crossing the line below at a point that you consider indicates how 





 No Pain       Extreme Pain 
 
 
Patient Global Assessment 
Consider all the ways in which your arthritis affects you at this time. 





 Very Well       Very Poorly 
 
Appendix 5b: Medical Outcomes Study Short-Form 36 survey  




































Appendix 5c: Global perceived effect scale  
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Please check each activity according to these directions: 
 
 
Check Column 1 ("Still Doing This Activity") if: 
 
you completed the activity unassisted the last time you had the need or 
opportunity to do so. 
 
 
Check Column 2 ("Have Stopped Doing This Activity") if: 
 
you have engaged in the activity in the past, but you probably would not 
perform the activity today even if the opportunity should arise. 
 
 
Check Column 3 ("Never Did This Activity") if: 
 












Human Activity Profile Test 
            By David M. Daughton and A. James Fix, Ph.D. 
 
 
Study Number: ___________________ 
Week Number: _____________________ 
                                                                                                                                                                  








1.  Getting in and out of chairs  
      or bed (without assistance) 
       
2.  Listening to the radio    
3.  Reading books, magazines or 
newspapers 
   
4.  Writing (letters, notes)    
5.  Working at a desk or table    
6.  Standing (for more than one minute)     
7.  Standing (for more than five 
minutes) 
   
8.  Dressing or undressing (without 
assistance) 
   
9.  Getting clothes from  
      drawers or closets 
   
10. Getting in or out of a car 
      (without assistance) 
   
11. Dining at a restaurant    
12. Playing cards/table games    
13. Taking a bath (no assistance 
needed) 
   
14. Putting on shoes, stockings or socks 
      (no assistance needed) 
   
15. Attending a movie, play, church  
      event or sports activity 
   
16. Walking 25 metres    
17. Walking 25 metres (non-stop)    
© 1980                                         
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 Human Activity Profile Test (cont.) 
 
 








18. Dressing/undressing (no rest 
      or break needed) 
   
19.Using public transportation or 
     driving a car  (150 kilometres or less) 
   
20. Using public transportation or 
     driving a car (150 kilometres or more) 
   
21. Cooking your own meals    
22. Washing or drying dishes    
23. Putting groceries on shelves    
24. Ironing or folding clothes    
25. Dusting/polishing furniture 
      or polishing cars 
   
26. Showering    
27. Climbing six steps    
28. Climbing six steps (non-stop)    
29. Climbing nine steps    
30. Climbing 12 steps    
31. Walking halfway around the block 
      on level ground 
   
32. Walking halfway around the block  
      on level ground (non-stop) 
   
33. Making a bed (not changing sheets)    
34. Cleaning windows    
35. Kneeling, squatting to do light work    
36. Carrying a light load of groceries    
37. Climbing nine steps (non-stop)    




Human Activity Profile Test (cont.)  
 
 








38. Climbing 12 steps (non-stop)    
39. Walking half a block uphill    
40. Walking half a block uphill  
      (non-stop)  
   
41. Shopping (by yourself)    
42. Washing clothes (by yourself)    
43. Walking one block on level   
       ground   
   
44. Walking two blocks on level  
       ground 
   
45. Walking one block on level  
      ground (non-stop) 
   
46. Walking two blocks on level  
      ground (non-stop) 
   
47. Scrubbing (floors, walls or cars)    
48. Making beds (changing sheets)    
49. Sweeping    
50. Sweeping (five minutes non-stop)    
51. Carrying a large suitcase or  
       bowling (one line) 
   
52. Vacuuming carpets    
53. Vacuuming carpets  
      (five minutes non-stop) 
   
54. Painting (interior/exterior)    
55. Walking around six blocks on level     
       ground 
   
56. Walking around six blocks on level  
       ground (non-stop) 
   
57. Carrying out the garbage    
                                     
     
175 
 
Human Activity Profile Test (cont.) 
 
 








58. Carrying a heavy load 
       of groceries/shopping 
   
59. Climbing 24 steps    
60. Climbing 36 steps    
61. Climbing 24 steps (non-stop)    
62. Climbing 36 steps (non-stop)    
63. Walking one and a half kilometres    
64. Walking one and a half kilometres 
      (non-stop) 
   
65. Running 100 metres or playing  
      softball/baseball 
   
66. Dancing (social)    
67. Doing calisthenics or aerobic 
      dancing (5 minutes non-stop) 
   
68. Mowing the lawn (power mower, 
      but not a riding mower) 
   
69. Walking three kilometres    
70. Walking three kilometres  
      (non-stop) 
   
71. Climbing 50 steps    
72. Shoveling, digging or spading    
73. Shoveling, digging or spading 
      (five minutes non-stop) 
   
74. Climbing 50 steps (non-stop)    
75. Walking five kilometres or  
       playing 18 holes of golf 
       without a riding cart 
   
76. Walking five kilometres (non- 
       stop) 
   

















78. Swimming 25 metres (non-stop)    
79. Bicycling one and a half  
      kilometres 
   
80. Bicycling three kilometres    
81. Bicycling one and a half  
      kilometres (non-stop) 
   
82. Bicycling three kilometres  
     (non-stop) 
   
83. Running or jogging half a kilometre    
84. Running or jogging one kilometre     
85. Playing tennis or racquetball    
86. Playing basketball (game play)    
87. Running or jogging half a kilometre 
(non-stop) 
   
88. Running or jogging one kilometre 
(non-stop) 
   
89. Running or jogging one and a half 
kilometres 
   
90. Running or jogging three kilometres    
91. Running or jogging five kilometres    
92. Running or jogging one and  
      a half kilometres in 12 minutes  
      or less 
   
93. Running or jogging three  
      kilometres in 20 minutes or less 
   
94. Running or jogging five  
      kilometres in 30 minutes or less 







Appendix 5e: Western Ontario and McMaster Universities 
Osteoarthritis Index information 
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